COMMISSION STAFF WORKING DOCUMENT Accompanying the document Report from the Commission to the European Parliament and the Council Implementation of the third Programme of Union action in the field of health in 2016
Date: 2019-08-05
Institutions: Directorate-General for Health and Food Safety, European Commission
Subjects: EU financing, EU policy, EU programme, disease prevention, health care, information system, orphan disease, patient's rights, public health

EN 

  EN 

   EUROPEAN COMMISSION  Brussels, 5.8.2019  SWD(2019) 316 final  COMMISSION STAFF WORKING DOCUMENT Accompanying the document Report from the Commission to the European Parliament and the Council Implementation of the third Programme of Union action in the field of health in 2016 {COM(2019) 365 final}  
 
 
TABLE OF CONTENTS 

JOINT ACTIONS  ________________________________________________________________  4 

1. 

Joint action on rare diseases — EUCERD JA  ______________________________________  4 

2. 

Joint action on a cross-border patient registries initiative — PARENT JA ________________  5 

Joint action on quality assurance exercises and networking on the detection of highly 
3. 
infectious pathogens — (QUANDHIP JA) & joint action on efficient response to highly dangerous 
and emerging pathogens at EU level (EMERGE JA)  ____________________________________  7 

4. 

Joint action on improving quality in HIV prevention — Quality Action JA  _______________  8 

PROJECTS ____________________________________________________________________  10 

1.  Activation of stratification strategies and results of the interventions on frail patients of 
healthcare services — ASSEHS  ___________________________________________________  10 

2.  Advancing care coordination & telehealth deployment programme — ACT  ____________  11 

3.  European Haemophilia Network — EUHANET  ___________________________________  12 

4.  Coordinated action in the aviation sector to control public health threats — AIRSAN _____  14 

OPERATING GRANTS ___________________________________________________________  15 

1.  Tuberculosis Europe Coalition: Strengthening the role of civil society within the TB response 
in Europe - TBEC  ______________________________________________________________  16 

2.  AIDS Action Europe — network continuity and innovation — AAE ____________________  18 

DIRECT GRANTS TO INTERNATIONAL ORGANISATIONS ________________________________  19 

1.  OECD: Preparation of EU Health Report — ‘State of Health in the European Union’ and 
country specific analysis ________________________________________________________  19 

2.  WHO: (The European Observatory on Health Systems and Policies) on country specific 
knowledge ___________________________________________________________________  19 

CALLS FOR TENDERS ___________________________________________________________  21 

1.  SERVICE CONTRACT: Development of a manual and toolbox for assessing the European 
Reference Networks  ___________________________________________________________  21 

2.  SERVICE CONTRACT: Study on the regulation of advanced therapies __________________  22 

3.  SERVICE CONTRACT: Organisation of a workshop targeting media, civil society and health 
professionals relating to the implementation of the Decision 1082/2013/EU on serious cross- 
border threats to health; and to conduct a study on the availability/supply capacities of critical 
medical countermeasures at Member State level and in the industry and to organise an inter-
sectoral table top exercise on outbreak coordination and response involving public health and 
other sectors _________________________________________________________________  23 

1 

 
 
4.  SERVICE CONTRACT: Organisation of a command post exercise on serious cross-border 
threats to health falling under the chemical and environmental categories ________________  25 

5.  SERVICE CONTRACT: Support of the implementation of Decision 1082/2013/EU especially as 
regards preparedness and response activities in the context of the Ebola Epidemic in West Africa, 
in particular the organisation of four workshops to be embedded as parallel sessions in a 
Commission organised conference ________________________________________________  27 

6.  SERVICE CONTRACT: Study on the mapping of best practices and development of testing 
methods and procedures for identifying characterising flavours in tobacco products  ________  29 

7.  SERVICE CONTRACT: Assessment of citizens’ exposure to tobacco marketing ___________  30 

8.  SERVICE CONTRACT: Study on the identification of potential risks to public health associated 
with the use of refillable electronic cigarettes and on the development of technical specifications 
for refill mechanisms — PRECISE  _________________________________________________  32 

HIGHLIGHTS OF CO-FUNDED ‘CROSS-CUTTING’ AND ‘OTHER’ ACTIONS ___________________  33 

1.  Dissemination activities carried out in 2016 _____________________________________  33 

2.  Other actions _____________________________________________________________  34 

Scientific Committees _______________________________________________________________  34 
Expert panel on effective ways of investing in health ______________________________________________  36 

CALLS FOR PROPOSALS ______________________________________________________________  38 
Project grants _____________________________________________________________________________  39 
European Reference Networks (sole beneficiary grants) ___________________________________________  41 
Operating grants  __________________________________________________________________________  43 

JOINT ACTIONS ____________________________________________________________________  45 

DIRECT GRANT AGREEMENTS AND PRESIDENCY CONFERENCES ______________________________  47 

PROCUREMENTS (SERVICE CONTRACTS)  ________________________________________________  50 

OTHER ACTIONS  ___________________________________________________________________  58 

DETAILED OVERVIEW OF THE REPORTING YEAR  __________________________________________  60 

Funding per thematic priority and financial instrument (all amounts in EUR) ____________________  60 

2 

 
 
 
 
 
Introduction 

This Commission staff working document accompanies the report on the implementation of the third health 

programme  in  2016.  The  report  provides  a  detailed  overview  of  all  the  actions  funded  under  the  annual 

work programme for 2016 (AWP 2016) and highlights  some of the key co-funded initiatives that aim to 

implement EU health policy and legislation. This staff working document also presents important results of 

actions co-funded under the second health programme, which ended in late 2015 and in 2016, and which 

were  in  some  cases  followed  up  by  actions  even  larger  in  scope  and  ambition.  It  includes  actions  on 

overarching themes (such as rare diseases and European Reference Networks, care coordination, registries, 

health  security  —  especially  in  light  of  the  Ebola  epidemic  and  tobacco)  which  have  been  included  in 

successive financing decisions. Lastly, it provides useful figures and statistics and the full list of co-funded 

initiatives and contracts financed under the third health programme's operating budget in 2016. 

Highlights of initiatives ending in the reporting year: examples of the programme’s results 

A number of initiatives co-funded under the second health programme, which ended in late 2015 and in 

2016, produced important results that were taken up and built on at national or EU level. Several of these 

are described below. More information about these and other projects and joint actions co-funded under the 

second  and  third  health  programmes  can  be  found  in  the  database  managed  by  the  Consumers,  Health, 
Agriculture and Food Executive Agency (Chafea)1. 

1 http://ec.europa.eu/chafea/health/index.html 

3 

 
 
 
 
 
                                                      
JOINT ACTIONS 

1. Joint action on rare diseases — EUCERD JA 

Background information 

The EUCERD JA ran from March 2012 to October 2015, with co-funding of up to EUR 2 994 162.00. It 

involved eight partners in eight EU countries (Belgium, Finland, France, Germany, Italy, Portugal, Spain 

and the United Kingdom). 

In mid-2015, the joint action on promoting implementation of recommendations on policy, information and 

data for rare diseases (RD-ACTION) took the work of EUCERD JA forward. Under this joint action, the 

partnership was enlarged to 35 partners from 22 countries. This solidified the commitment of the EU and 

other countries involved to work together on rare diseases. 

Brief description 

Supporting the activities and mandate of the European Union Committee of Experts on Rare Diseases, the 
EUCERD2 joint action comprised five main areas of work: 

- 

- 

implementing plans and strategies for rare diseases at national level; 

standardising rare disease nomenclatures at international level; 

-  mapping the specialised social services already available; 

- 

integrating rare diseases into mainstream social policies and services; and 

-  mainstreaming rare diseases initiatives across EU policy areas and across Member States. 

Specific results 

As  a  policy  support action,  the joint action  mainly  produced  guidance  and  evidence-based  tools  for  rare 

disease policies and activities at national and EU level. 

Key outcomes/outputs include: 

2  The  European  Union  Committee  of  Experts  on  Rare  Diseases  (EUCERD)  was  replaced  by  the  European 
Commission Expert Group on Rare Diseases. 

4 

 
 
 
 
                                                      
- 

increased  visibility  of  rare diseases  in international  disease  nomenclatures  (ICD-11,  OrphaCodes 

and human phenotype terminologies), which improved the recognition of rare diseases by national 

health and social insurance systems; 

- 

faster  implementation  of  comprehensive  national rare  diseases action  plans (the  action  organised 

24 national conferences bringing together all the stakeholders); 

-  wider  recognition  of  the  value  of  specialised  social  services  thanks  to  the  extensive  mapping  of 

existing services and guidelines for developing them at national level; 

- 

quality criteria for centres of expertise and European Reference Networks (ERNs) in the field of 

rare  diseases:  the  joint  action's  work  was  endorsed  on  the  recommendation  of  the  European 

Commission  Expert  Group  on  Rare  Diseases  and  the  criteria  were  integrated  in  the  European 

Commission's    delegated  and  implementing  decisions  under  Directive  2011/24/EU  on  patients’ 

rights in cross-border health care3; 

- 

a  minimum  data  set  for  rare  diseases  patient  registries  produced  in  collaboration  with  the 

EPIRARE project and the PARENT JA. 

The action's results are available on the project website4 and in Chafea’s health programme database5. 

2. Joint  action  on  a  cross-border  patient  registries  initiative  — 

PARENT JA 

Background information 

The PARENT JA ran from May 2012 to December 2015 with co-funding of up to EUR 2 016 231.00. It 

involved  11  partners  in  10  EU  countries  (Croatia,  Finland  Greece,  Hungary,  Italy,  Malta,  Portugal, 

Slovakia, Slovenia and Spain). 

3 Commission delegated decision 2014/286/EU of 10 March 2014 defining the criteria and conditions that healthcare 
providers and the ERNs should fulfil. Commission implementing decision 2014/287/EU of 10 March 2014 defining 
criteria for establishing and evaluating ERNs. 

4 http://www.eucerd.eu/ 

5 https://webgate.ec.europa.eu/chafea_pdb/health/projects/20112201/summary 

5 

 
 
 
 
 
 
                                                      
Brief description 

The PARENT JA aimed to provide Member States with guidelines and recommendations on improving the 

quality  of  patient  registries  and  their  readiness  for  interoperability  to  encourage  and  improve  the  use  of 

clinical data for public health purposes. 

The PARENT JA: 

- 

provided  a  comprehensive  overview  of  the  current  situation  in  EU  countries  regarding  patient 

registries; 

- 

created  a  pilot  ‘Registry  of  Registries  of  national  patient  registries’  and  developed 

recommendations,  guidelines  and  IT  tools  for  efficient  and  rational  governance  of  patient 

registries; 

- 

provided a plan of activities and policies for registries to support the implementation of Directive 
2011/24/EU on patients’ rights in cross-border health care6; and 

- 

developed  guidance  on  secondary  use  of  registry  data,  including  the  Registry  of  Registries  and 

methodological and governance guidelines, to be used by patient registration initiatives beyond the 

joint action's lifecycle. 

Specific results 

The PARENT JA provided guidance to Member States on developing interoperable and coherent patient 

registries  with  comparable  elements  to  support  existing  EU  projects.  This  took  the  form  of  a  toolkit 

covering  topics  such  as  how  to  set  up  a  patient  registry,  what  ICT  tools  to  use,  the  recommended 

information models, and the relationship to and dependence on electronic health records. 

It also introduced a ‘Knowledge Management Platform — Wiki’ containing documents such as guidelines, 

state-of-the-art reviews and best practices so that all Member States can access such information. 

The action's results are available on the project website7 and in Chafea’s health programme database8. 

6 https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A32011L0024 

7 http://www.parent-ror.eu/#/ 

8 https://webgate.ec.europa.eu/chafea_pdb/health/projects/20112302/summary 

6 

 
 
 
 
 
 
                                                      
3. Joint  action  on  quality  assurance  exercises  and  networking  on 
the  detection  of  highly  infectious  pathogens  —  (QUANDHIP 
JA) & joint action on efficient response to highly dangerous and 
emerging pathogens at EU level (EMERGE JA) 

Background information 

The QUANDHIP JA ran from August 2011 to the end of January 2015 with co-funding of EUR 3 315 981. 

It involved 37 highly specialised and advanced laboratories from 21 European countries (Austria, Belgium, 

Bulgaria,  the  Czech  Republic,  Denmark,  Estonia,  Finland,  France,  Germany,  Greece,  Hungary,  Italy, 

Latvia, Lithuania, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the United Kingdom). 

The EMERGE JA built on this work, running from June 2015 to the end of March 2019 and extended the 

partnership to over 40 diagnostic laboratories. It aimed to: (i) evaluate new diagnostic methods for high-

threat  pathogens;  (ii)  carry  out  quality  assurance  and  training;  and  (iii)  ensure  best  approaches  for 

laboratory responsiveness during outbreaks. 

Brief description 

The primary aim was to bring together two pre-existing EU laboratory networks — one dealing with high-

threat bacteria (risk group 3) and the other with highly infectious viruses (risk group 4). The QUANDHIP 

network ensured the extensive exchange of best diagnostic strategies to support a joint European response 

to outbreaks of highly pathogenic infectious agents, including the generation of a bio-diverse repository of 

reference  materials.  The  joint  action  also  provided  a  supportive  European  infrastructure  and  strategy  for 

External Quality Assurance Exercises (EQAE), training, and biosafety/biosecurity quality management. 

Specific results 

Key achievements of QUANDHIP JA support include: 

-  The network on highly pathogenic bacteria (NIB) performed three EQAE focused on B. anthracis, 

Y. pestis, F. tularensis, C. burnetii, B. pseudomallei, B. mallei and B. melitensis-group. 

-  The  network  on  highly  pathogenic  viruses  (NIV)  performed  EQAE  focusing  on  the  Lassa, 

Marburg and Ebola viruses. 

-  The  joint  action  produced  a  revised  integrated  European  checklist  for  laboratory  biorisk 

management in the handling of high consequence risk group 3 and 4 agents (ECL-Biorisk). 

7 

 
 
 
-  The  joint  action  developed  standard  operational  procedures  (SOP)  for  coordinating  laboratory 

activities during outbreaks. 

The  SOP  was  applied  in  the  following  specific  cases:  (a)  when  the  network  provided  technical 

support  with  the  shipping  of  and  testing  for  Hantavirus  infections;  (b)  when  assessing  the 

diagnostic  capabilities  to  combat  the  novel  coronavirus  (hCoV-EMC)  in  different  countries;  (c) 

during the laboratory investigation of anthrax cases among heroin users; and most recently (d) in 

the cases of H7N9 influenza and the 2014-2015 Ebola outbreak. 

For the Ebola outbreak in particular, the network allowed EU countries to confirm suspected cases. 

These experiences were all included in an updated SOP. 

The EMERGE JA has built on these concrete outcomes. It has: (i) conducted additional quality assurance 

exercises;  (ii)  expanded  the  training  of  participating  laboratories  accrediting  them  as  national  reference 

laboratories; and (iii) demonstrated the benefits to the participating Member States. 

The action's results are available on the project website9 and in Chafea’s health programme database10. 

4. Joint action on improving quality in HIV prevention — Quality 

Action JA 

Background information 

The  Quality  Action  JA  ran  from  March  2013  to  the  end  of  February  2016  with  co-funding  of 

EUR 1 493 175.  It  involved  25  associated  partners  from  22  countries  (Austria,  Belgium,  Bulgaria,  the 

Czech  Republic,  Denmark,  France,  Germany,  Greece,  Ireland,  Italy,  Hungary,  Latvia,  the  Netherlands, 

Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom). 

Brief description 

This  joint  action  aimed  to  improve  the  quality  of  the  response  to  HIV  and  AIDS  across  Europe  by 

integrating  evidence-based  quality  improvement  (including  quality  assurance)  practices  into  HIV 

prevention. 

With  key  partners  in  the  area,  the  joint  action  developed  practical  tools  and  materials  to  maximise  the 

quality of HIV prevention projects and programmes in the participating countries. 

9 https://www.emerge.rki.eu/Emerge/EN/Content/Quandhip/quandhip_node.html 

10 https://webgate.ec.europa.eu/chafea_pdb/health/projects/20102102/summary 

8 

 
 
 
 
                                                      
The Quality Action JA also developed two key documents to gain policy support and create an enabling 

environment for quality improvement: 

‒ 

the  Charter  for  Quality  in  HIV  Prevention11,  which  sets  out  quality  principles,  criteria  and  key 

activities  for  improving  quality  and  gives  practitioners,  experts,  policy  makers  and  others  the 

opportunity to commit to improving their work in HIV prevention; and  

‒  The  Policy  Kit12,  which  provides  policy  makers  with  the  arguments  and  concrete  actions  for 

integrating quality improvement into HIV prevention policies, strategies and action plans. 

Specific results 

The Quality Action JA yielded the following tangible results: 

- 

five  practical  quality  improvement  tools13  (with  relevant  supporting  materials)  in  a  variety  of 

European languages: (i) Quality in prevention (QIP); (ii) Participatory quality development (PQD), 

(iii)  Succeed  —  a  knowledge  base  tool;  (iv)  the  SCHIFF  (programme  tool)  method;  and  (v)  a 

quality assurance tool for health promotion and prevention for people who inject drugs ('PIQA'); 

- 

- 

a database of 98 case studies of practical quality improvement tool applications; and 

a broad consensus on principles and criteria for quality improvement, represented by the Charter 

for Quality in HIV prevention and a policy kit as a concise advocacy tool for further dissemination. 

In terms of capacity building, this innovative partnership created a large network of experts, having trained 

more than 400 quality improvement trainers and facilitators from 25 different European countries. It also 

succeeded in integrating quality improvement in HIV prevention. 

The action's results are available on the project website14 and in Chafea’s health programme database15. 

11 https://www.qualityaction.eu/images/qact_policykit_charter.pdf 

12 https://www.qualityaction.eu/images/qact_policykit_03.pdf 

13 https://www.qualityaction.eu/wordpress/wp-content/uploads/2016/03/QualityAction_ToolSelectionGuide_20160224-1.pdf 

14 https://www.qualityaction.eu/ 

15 https://webgate.ec.europa.eu/chafea_pdb/health/projects/20122102/summary 

9 

 
 
                                                      
PROJECTS 

1. Activation  of  stratification  strategies  and  results  of  the 
interventions on frail patients of healthcare services — ASSEHS 

Background information 

The ASSEHS project ran from March 2013 to July 2016 with co-funding of EUR 1 342,356. It involved 

eight associated partners from four countries (France, Italy, the Netherlands and Spain). 

Brief description 

In 2013, the health programme started to co-fund actions to support the European Innovation Partnership 

on  Active  and  Healthy  Ageing  (EIP-AHA),  a  flagship  initiative  to  address  the  challenges  of  an  ageing 

society. To face the challenge, EU health systems are becoming more proactive, adopting integrated care 

models and using health risk management tools to provide personalised and patient-centred services. 

Such 'risk stratification tools' can help to identify complex frail and high-risk patients and keep them on 

health  services'  radars.  More  importantly,  these  tools  can  ensure  appropriate  interventions  for  this 

vulnerable  population  group  and  help  people  remain  in  their  homes  and  communities  for  as  long  as 
possible and delay or entirely avoid them needing to be cared for in an acute care setting16. 

Specific results 

The ASSEHS project has delivered: 

- 

an extensive analysis of the various risk stratification tools17 available (note that frail patients are 

not identified by simple algorithms and that current models use a variety of important data, such as 

diagnoses,  socio-demographic  data,  pharmacy  data,  prior  use  of  health  care  and  socio-economic 

data); 

- 

a white paper on the deployment of stratification methods, supporting the transferability value for 

other regions and healthcare systems. 

16 For every 1 000 patients, there will likely be close to 200 patients (20%) living with more than one chronic disease 
who  could  benefit  from  more  intensive  support.  As  an  example,  in  the  United  States  (there  are  no  such  studies 
covering  the  entire  EU),  this  20%  of  the  population  accounts  for  80%  of  total  health  care  spending.  And  of  these 
‘higher need’ patients, 5% account  for nearly  half of US health expenditure. Furthermore, health care spending  for 
people with five or more chronic conditions is 17 times higher than for people with no chronic conditions. 

17  https://ec.europa.eu/eip/ageing/repository/population-risk-stratification-deployment-stratification-methods-basque-
country_en 

10 

 
 
 
                                                      
An  analysis  of  risk  stratification  models  and  the  lessons  learnt  from  their  use  in  the  participating  EU 

countries  has  concluded  that  they  are  highly  useful  and  should  be  extended  to  other  EU  countries  and 

regions. 

The action's results are available on the project website18 and in Chafea’s health programme database19. 

2. Advancing  care  coordination  & 

telehealth  deployment 

programme — ACT 

Background information 

The  ACT  programme  ran  from  March  2013  to  the  end  of  February  2016  with  co-funding  of 

EUR 1 596 383.63.  It  involved  14  partners  from  six  countries  (Germany,  Greece,  Italy,  the  Netherlands, 

Spain and the United Kingdom). 

Brief description 

Many consider connected care to be essential for more efficient, patient-centred, continuous and integrated 

health  and  social  care  for  ageing  people  in  the  EU.  However,  although  many  local  connected  care  pilot 

programmes  are  successful,  they  fail  to  scale  up,  even  at  national level,  and  health  systems  do  not  fully 

benefit from their potential impact. 

The ACT consortium carried out a comprehensive two-and-a-half year scientific evaluation of data from 

different connected health programmes in five European regions and conducted 2 500 surveys and group 

interviews  with  patients,  care  providers,  experts  and  other  stakeholders.  The  cross-border  nature  of  this 

evaluation  is  particularly  valuable  as  it  allows  us  to  compare  different  EU  programmes  and  learn  from 

them. 

The  action's  final  report  provides  local  and  regional  health  authorities  with  solutions  for  large-scale 

deployment  of  connected  care  interventions  across  Europe.  This  has  the  potential  to  transform  care  for 

millions of chronically ill people and generate significant savings for EU healthcare systems. 

Specific results 

18 http://assehs.eu/ 

19 https://webgate.ec.europa.eu/chafea_pdb/health/projects/20131204/summary 

11 

 
 
 
 
                                                      
The ACT programme was able to: 

- 

- 

- 

- 

- 

gather data and good practices from different regions across the EU; 

determine a baseline for how care coordination and telehealth works in these regions; 

conduct an iterative evaluation of care structures and procedures; 

select best practices; and 

disseminate findings so that good practices can be extended to other regions. 

Its key outcome is the evaluation of how to effectively deploy coordinated care and telehealth services on a 

large  scale.  Although  this  evaluation  was  based  on  the  five  participating  regions  (Catalonia,  the  Basque 

Country, Lombardy, Groningen and Scotland), its conclusions can be applied throughout the EU 

These results have been published in a best practice ‘cookbook’20, which describes how these insights can 

be used to extend care coordination and telehealth to other regions in Europe. 

The action's results are available on the project website21 and in Chafea’s health programme database22. 

3. European Haemophilia Network — EUHANET 

Background information 
The  EUHANET  project23  ran  from  June  2012  to  the  end  of  November  2015  with  co-funding  of  up  to 

EUR 885 614.  It  involved  six  partners  from  four  countries (the  United Kingdom,  Belgium,  Italy  and  the 

Netherlands). 

Brief description 

EUHANET was set up to improve care for European citizens with inherited bleeding disorders and was a 

'pilot' ERN. Although knowledge about these disorders is improving over time, the related improvement in 

treatment  and  care  varies  across  Europe.  European  health  systems  are  diverse  and  patient  care  varies 

significantly, for instance in terms of the quality of facilities and the types of therapies available. 

20 https://www.act-programme.eu/sites/all/themes/act/files/ACT_Cookbook_final.pdf 

21 https://www.act-programme.eu/ 

22 https://webgate.ec.europa.eu/chafea_pdb/health/projects/709770/summary 

23 http://www.euhanet.org/ 

12 

 
 
 
 
                                                      
EUHANET had four main areas of activity: 

- 

- 

assessing and classifying the quality of care currently provided by Haemophilia centres in Europe; 

creating  and  maintaining  a  website  to  provide  information  on  rare  bleeding  disorders  and  their 

treatment; 

-  monitoring the safety of treatments for inherited bleeding disorders via the European Haemophilia 

Safety Surveillance24 (EUHASS) system; and 

- 

collecting prospective information on the diagnosis, care and treatment of patients with extremely 
rare  bleeding  disorders  to  enter  into  the  Prospective  Rare  Bleeding  Disorders  Database25  (PRO-

RBDD). 

Specific results 

EUHANET developed and put in place a European Haemophilia Centre certification scheme. It produced a 

standard  document  to  categorise  treatment  centres  into  one  of  two  types:  (i)  a  European  Haemophilia 

Treatment Centre (EHTC); or (ii) a European Haemophilia Comprehensive Care Centre (EHCCC). 

EUHANET created and still runs the Haemophilia central website26, which is a one-stop-shop for finding 

key information about inherited bleeding disorders. 

The  website  also  includes  links  to  the  Haemophilia  Centre  Locator,  a  user-friendly  search  engine  that 

locates European Haemophilia Centres. This is accessible from any computer, tablet or mobile phone. It 

gives the five nearest Haemophilia centres for any address, shows them on a map, and provides addresses 

and contact information for each centre. This is particularly useful for patients with bleeding disorders who 

are travelling in Europe. 

EUHANET continued and extended the EUHASS adverse event reporting system that monitors the safety 

of treatments for people with Haemophilia and other inherited bleeding disorders in Europe. It also further 

developed the Prospective Rare Bleeding Disorders Database (PRO-RBDD). 

The action's results are available on the project website27 and in Chafea’s health programme database28. 

24 https://www.euhass.org/ 

25 http://eahad.org/prospective-rare-bleeding-disorders-database-pro-rbdd/ 

26  http://www.haemophiliacentral.org/. This website provides information on bleeding disorders, treatment guidelines, 
clinical  trials,  clotting  factor  concentrates,  haemophilia  centre  locations  and  facilities,  aggregated  data  from 
EUHASS,  quality  control  schemes,  haemostatic  gene  mutations,  haemophilia  service  provision  in  European 
countries. It allows users to ask generic questions and provides a news service and Haemtrack, and a telemedicine 
system whereby patients can enter information online about their clotting factor use at home. 

27 http://www.euhanet.org/ 

13 

 
 
                                                      
4. Coordinated  action  in  the  aviation  sector  to  control  public 

health threats — AIRSAN 

Background information 

The AIRSAN project ran from April 2013 to the end of December 2015 with co-funding of EUR 598 566. 

It involved seven partners in five EU countries (Belgium, Germany, Greece, the Netherlands and Poland), 

and  20  collaborating  partners  representing  international  organisations  working  on  aviation  and  health 

(WHO, ICAO and EASA). 

Brief description 

AIRSAN's general objective was to support an efficient, multi-sector, multi-stakeholder response to public 

health threats in air transport that is consistent across the EU. 

To  achieve  this,  the  project  actively  involved  national  public  health  and  civil  aviation  authorities,  local 

public health authorities working in airports, airport and airline management and medical services across 

the EU. 

Specific results 

- 

setting up the AIRSAN network of national public health and civil aviation authorities, local public 

health authorities in airports, airport and airline management and medical services across the EU; 

- 

setting  up  the  AIRSAN  communication  platform  linked  to  the  AIRSAN  website  to  gather 

information and exchange information; 

- 

conducting a review of existing guidance documents on the control of public health threats in  air 

transport, resulting in the AIRSAN bibliography; 

- 

developing and testing AIRSAN guidance documents on the control of public health threats in air 

transport; and 

- 

developing  the  AIRSAN  training  tool  to  help  countries  implement  the AIRSAN  guidance 

documents. 

The action's results are available on the project website29 and in Chafea’s health programme database30. 

28 https://webgate.ec.europa.eu/chafea_pdb/health/projects 

29 http://www.airsan.eu/ 

30 https://webgate.ec.europa.eu/chafea_pdb/health/projects/20121102/summary 

14 

 
 
 
 
                                                                                                                                                                             
OPERATING GRANTS 
13  non-governmental  organisations  (NGOs)  that  signed  a  framework  partnership  agreement  (FPA)  in 
201431 were invited to submit their proposals for a specific grant agreement (SGA) under the 2016 AWP to 
cover their annual recurrent operational expenses for the financial year 201732. 

10 FPAs and their SGAs respond to Objective 1 of the third health programme:  ‘Promote health, prevent 

diseases  and  foster  supportive  environments  for  healthy  lifestyles  taking  into  account  the  ‘health  in  all 

policies’  principle’,  and  the  other  three  respond  to  Objective  4:  ‘Facilitate  access  to  better  and  safer 

healthcare for Union citizens’. 

Table 1: List of applicant organisations that were awarded an FPA and subsequent SGAs 

Organisation 

Alzheimer Europe 

World Obesity Federation 

Smoke Free Partnership 

Results Education 

European Network for Smoking Prevention 

Deutsche AIDS-HILFE EV 

SO Europe Eurasia Foundation 

Association européenne des Ligues contre le Cancer 

European Public Health Alliance 

Association Médecins du Monde 

Stichting Health Action International 

Forum Européen des Patients (FPE) 

European Organisation For Rare Diseases Association 

31  14  FPAs  were  signed  with  successful  applicant  organisations  for  2015-2018,  making  them  eligible  for  financial 
support on an annual basis for each of the years covered by the FPA. 

32 One of the 14 applicant organisations awarded an FPA went bankrupt in 2015 and therefore has not participated in 
the call for SGAs in 2016. 

15 

 
 
                                                      
Throughout  2016,  in  line  with  their  SGAs,  the  above  organisations  achieved  their  objectives,  produced 

work of value to their stakeholders and supported the Directorate-General for Health and Food Safety (DG 

SANTE)  policy  initiatives  in  their  areas  of  activity.  An  example  of  the  work  and  outcomes  of  two 

organisations with an SGA that are active in the area of tuberculosis is presented below. 

1. Tuberculosis  Europe  Coalition:  Strengthening  the  role  of  civil 

society within the TB response in Europe  - TBEC 

Background information 

The Tuberculosis Europe Coalition (TBEC) operating grant ran from January 2015 to December 2017 with 

co-funding of EUR 245 670 (or around EUR 82 000 per year). During this period, the network membership 

expanded to 303 members, covering 31 countries in the European region, including 18 EU countries and all 

tuberculosis (TB) high burden countries. 

Brief description 

The  TBEC  is  an  advocacy  network  that  brings  together  civil  society  representatives  (individuals  and 

organisations) from across the WHO European Region to strengthen the role of civil society in the regional 

response to TB and to increase the political and financial commitment required to effectively control the 

epidemic in the region. 

TBEC operations aimed to: 

-  map civil society stakeholders across the WHO European Region; 

- 

- 

facilitate access to information and resources for capacity building for target groups; 

conduct outreach to civil society across the region to expand the network and build relationships 

with target groups; 

- 

engage with decision makers on behalf of civil society across the region; and 

-  manage the network effectively to implement the annual work programme. 

Specific results 

TBEC helped strengthen the role of civil society in Europe's TB response, with the mapping of civil society 

working on TB in 43 countries in the region, including all 28 EU Member States. 

16 

 
 
 
 
TBEC conducted a qualitative and quantitative mapping of civil society stakeholders in 30 target countries, 

including  at  least  15  EU  countries.  Its  working  method  included  country  visits  (e.g.  Romania),  online 

training  and  webinars, a ‘join  us’ invitation  on  the  website,  attending  various  conferences and  meetings, 

and networking. 

Target  countries  including  Latvia,  Lithuania,  Estonia,  Romania  and  Bulgaria  were  mapped  to  strengthen 

TBEC’s understanding of the transition process to solely national funding of TB diagnostics, treatment and 

prevention  programmes  in  upcoming  years.  The  civil  society  mapping  in  Romania  and  Bulgaria  also 

provided better understanding of key TB-related civil society issues, ahead of the Bulgarian EU Presidency 

in 2018. 

In 2016 TBEC also published the annual report on ‘How to leverage European Union funding for health in 

Eastern Europe and Central Asia’ and a position paper entitled ‘Transitioning from donor support HIV and 

TB programmes in Eastern Europe and Central Asia: challenges and effective solutions’. 

Both  documents  addressed  the  transition  process  in  middle-income  countries  that  will  experience 

withdrawal of international donor funding on TB in the upcoming years. The policy paper aims to convince 

international  and  regional  decision  makers  and  donors,  as  well  as  national  governments,  that  a  rushed 

transition process can undermine previous achievements in TB diagnostics, treatment and prevention, as in 

the  case  of  Romania.  The  thematic  report  provides  more  information  about  various  EU  funding 

opportunities to civil society organisations in the WHO Europe region to help ease the transition process 

and supplement low levels of national funding. Both the thematic report and policy paper were translated 

into Russian, which was highly appreciated by civil society in the European region, including in the Baltic 

countries and Bulgaria. 

In  2016,  the  TBEC  Secretariat  also  gave  two  webinars  (in  Russian  and  English).  Throughout  the  year, 

TBEC continued to engage with the EU, the WHO and the Global Fund to shape TB policy (e.g. transition, 

ambulatory  care  and  antimicrobial  resistance)  by  participating  in  meetings  and  conferences  and  by 

publishing  policy  reports.  TBEC  Secretariat  members  also  continued  to  chair  the  WHO  Regional 

Collaborative Committee (RCC) on TB, continuously strengthening their collaboration with WHO Europe 

and other technical partners. 

Further information is available on TBEC's website33 and in Chafea’s health programme database34. 

33 http://www.tbcoalition.eu/ 

34 https://webgate.ec.europa.eu/chafea_pdb/health/projects 

17 

 
 
 
                                                      
2. AIDS Action  Europe  —  network  continuity  and  innovation  — 

AAE 

Background information 

The AAE operating grant ran from January 2015 to December 2017 with co-funding of up to EUR 773 277 

(or around EUR 258 000 per year). 

AAE  is  a  central  player  at  European  level  in  HIV/AIDS  policies  and  interventions,  and  pursues  its 

objectives in cooperation with a comprehensive, pan-European network. AAE is a European-wide network, 

covering EU Member States, neighbouring countries and countries in Eastern Europe and Central Asia. It 

comprises  440  NGOs,  national  networks,  AIDS  service  organisations,  activists  and  community-based 

groups of people living with HIV in 47 countries in the WHO European Region. It has 162 members in the 

28 EU Member States and six in Norway and Switzerland. 

Brief description 

AAE’s work under the FPA 2015-2017 follows the three principles stated in the 2016 SGA: 

- 

that civil society’s contributions to regional and national HIV/AIDS policies and programmes are 

effective and meaningful; 

- 

that a strong and effective working network is established by improved collaboration, linking and 

learning, and good practice exchange related to HIV/AIDS among NGOs, networks, policy makers 

and other stakeholders; and 

- 

that the functioning of the network is ensured by optimised internal management processes. 

Specific results. 

AAE's results/achievements include: 

- 

improved  impact  of  the  Civil  Society  Forum  on  European  HIV/AIDS,  viral  hepatitis  and 

tuberculosis policy development, thanks to meetings organised on EU policies; 

- 

the HIV/AIDS Clearinghouse, which enables quick and easy cross-border information sharing, was 

used  more  actively  and  by  a  wider  audience  (20  publications  were  uploaded  onto  the 

Clearinghouse,  48  news  and  events  were  posted  on  the  website  -  mainly  in  the  bilingual  e-

newsletter);  

-  AAE  increased  its  social media  output,  with  156  Facebook  posts,  115  tweets  and  104  vkontakte 

posts shared; 

- 

regional trainings were conducted on the topic of affordability and pricing of medications; 

18 

 
 
 
 
- 

the  European  HIV  Legal  Forum  network  was  created  to  improve  access  to  HIV  prevention, 

counselling and testing, treatment, care and support for all those who have limited access to HIV 

services due to legal obstacles; and 

-  AAE  participated  to  the  UNAIDS  Programme  Coordinating  Board  in  2016-2017,  ensuring  that 

European issues were heard and properly addressed in the global agenda. 

More information is available on the AAE's website35 and in Chafea’s health programme database36. 

DIRECT GRANTS TO INTERNATIONAL ORGANISATIONS 

1. OECD: Preparation of EU Health Report — ‘State of Health in 

the European Union’ and country specific analysis 

2. WHO:  (The  European  Observatory  on  Health  Systems  and 

Policies) on country specific knowledge 

In 2016, the Commission launched the first two-year cycle of the State of Health in the EU, leading to the 
publication in 2017 of the first country health profiles and the companion report. 

This was made possible by two direct grants: 

‒  The direct grant to the Organisation for Economic Cooperation and Development (OECD) that ran 

for 24 months, from July 2016 to June 2018 with a maximum co-funding of EUR 1 200 000. 

‒  The  direct  grant  to  the WHO  hosting  the  European  Observatory  on  Health  Systems  and  Policies 
that  ran  for  18  months,  from  May  2016  to  December  2017,  with  a  maximum  co-funding  of 
EUR 750 00037. 

Background information 

The State of Health in the EU initiative aimed to bring together the expertise and knowledge of the OECD 
and  the  European  Observatory  on  Health  Systems  and  Policies  and  to  create  a  mechanism  for  mutual 
learning and voluntary exchange to help Member States in their evidence-based policy- making. 

It followed on from other significant efforts to align health information collected by the EU, the OECD and 
the WHO. 

Brief description 

35 http://www.aidsactioneurope.org 

36 https://webgate.ec.europa.eu/chafea_pdb/health/projects 

37 The EU co-funding also covered work on antimicrobial resistance. 

19 

 
 
                                                      
The  State  of  Health in  the  EU  is  a  European  Commission  initiative  to  provide policy  makers,  interested 
stakeholders  and  health  professionals  with  factual,  comparative  data  and  insights  into  health  and  health 
systems in EU countries. 

The two-year State of Health in the EU cycle has four main stages: 

- 

- 

the 'Health at a Glance: Europe' report, prepared by the OECD, gives a horizontal starting point; 

the  individual  country  health  profiles,  adapted  to  the  context  and  specific  situation  of  each  EU 

country, assesses the strengths and challenges of their respective health systems; 

- 

a  companion  report  published  alongside  the  country  health  profiles  draws  cross-cutting 

conclusions,  links  common  policy  priorities  across  EU  countries,  and  explores  the  scope  for 

mutual learning; and in addition 

- 

at  the  close  of  the  two-year  cycle,  health  authorities  in  EU  countries  can  request  voluntary 

exchanges with the experts behind the State of Health in the EU, to discuss findings and potential 

policy responses. 

Specific results 

The concise, policy relevant profiles were based on a transparent and consistent methodology, using both 
quantitative and qualitative data, yet flexibly adapted to the context of each EU Member State. 

Each country health profile provided a short synthesis of: 

- 

- 

- 

- 

health status; 

the determinants of health, focusing on behavioural risk factors; 

the organisation of the health system; and 

the effectiveness, accessibility and resilience of the health system. 

The companion report drew cross-cutting conclusions from the 28 country health profiles on: 

- 

the  added  value  of  a  shift  towards  health  promotion  and  disease  prevention  and  of  measures  to 

counter health inequalities; 

- 

the key role for primary care to guide patients through the health system and help avoid wasteful 

spending; 

- 

- 

the prospective of integrated care to reduce fragmented service delivery; 

the  positive  impact  of  proactive  health  workforce  planning  and  forecasting  in  increasing  health 

systems' resilience to future developments; and 

- 

the potential of patient-centred data for policy and practice. 

20 

 
 
 
 
 
CALLS FOR TENDERS 

1. SERVICE  CONTRACT:  Development  of  a  manual  and 

toolbox for assessing the European Reference Networks 

Background information 

The service contract was carried out by the PACE-ERN consortium and was led by EURORDIS (members 

of the consortium include Accreditation Europe ASBL, European Hospital and the Healthcare Federation). 

The  maximum  contract  price  was  EUR 500 000.  It  kicked  off  in  December  2014  with  a  duration  of  16 

month. 

Brief description 

This service contract aimed to help the Commission develop the methodology and technical tools to assess 

the ‘Networks and healthcare providers’ proposals under Article 12 of Directive 2011/24/EU on patients’ 
rights in cross-border healthcare38 and relevant implementing measures. 

The  Directive  requires  that  the  Commission  support  Member  States  in  developing  European  Reference 

Networks  (ERNs)  between  healthcare  providers  and  centres  of  expertise  by  establishing  the  legal 

framework  for  such  networks.  The  Commission  was  therefore  tasked  with  adopting  implementing 

measures on the criteria and conditions to be fulfilled by such networks and healthcare providers, and on 

the establishment and evaluation of the networks. 

The  Commission  adopted  Delegated  Decision  2014/286/EU39  on  10  March  2014  on  the  criteria  and 

conditions that networks and healthcare providers that want to join a network must fulfil. It also adopted 
Implementing Decision 2014/287EU40 on the criteria for the establishment and evaluation of the networks. 

Both Decisions entered into force on 27 May 2014. 

The implementing decision establishes that each applicant network and its healthcare providers should be 

technically assessed according to the criteria set out in Delegated Decision 2014/286/EU. The assessment 

38 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32011L0024&from=EN 

39  https://publications.europa.eu/en/publication-detail/-/publication/dba7b357-dd8b-11e3-8cd4-

01aa75ed71a1/language-en 

40 https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ%3AJOL_2014_147_R_0007 

21 

 
 
 
 
                                                      
should include an exhaustive documentation review and on-site audits of a selected number of applicants. 

It should be carried out by an independent assessment body appointed by the European Commission on the 

basis of a common assessment manual. 

Specific results 

The  service  contract  resulted  in  the  development  of  an  ERN  assessment  manual  and  toolbox41  that 

addresses all assessment steps from the publication of the call for networks to their approval and covers the 

materials and methods to be used and the expected end products. 

The assessment manual and toolbox were used to assess candidate ERNs that applied under the related call 

for expression of interest launched by Chafea on behalf of the European Commission in 2016. 

Chafea  selected  independent  assessment  bodies  (IABs)  which, based  on  the  manual and toolbox,  carried 

out the technical assessment of the ERN proposals. For example, they: 

  assessed  the  documentation  submitted  by  the  candidate  networks  and  applicant  health  care 

providers; 

  conducted on-site audits of applicant healthcare providers; and 

  produced  a  final  technical  assessment  report  of  the  network  proposal  and  applicant  healthcare 

providers. 

The above steps underpinned the Board of Member States' decision on December 2016 to approve 

the  23  applicant  ERNs  in  line  with  the  conditions  and  requirements  of  the  Implementing 

(2014/287/EU) and Delegated Decision (2014/286/EU). 

2. SERVICE  CONTRACT:  Study  on 

the  regulation  of 

advanced therapies 

The  contractor  ECORYS  NEDERLANDS  B.V  (the  Netherlands  with  consortium  members  National 

Institute for Health and Welfare (Finland) and Universita Cattolica Del Sacro Cuore (Italy) carried out the 

study on the regulation of advanced therapies outside the EU). The contract ran for 10 months starting in 

April 2015 for a maximum price of EUR 161 500. 

41 https://ec.europa.eu/health/sites/health/files/ern/docs/amt_technicaltoolbox_en.pdf 

22 

 
 
 
                                                      
Brief description 

This  service  contract  aimed  to  produce  a  study  with  comprehensive  information  about  the  advanced 

therapies already are available to patients and about those that are under development in the USA, Canada, 

Japan  and  South  Korea,  and  about  the  regulatory  frameworks  governing  advanced  therapies  in  these 

countries. 

The  outcome  of  the  study  was  intended  to  feed  into  a  reflection  process  on  EU  legislation  on  advanced 

therapies to ensure that the legislation is adequately adapted to the needs of this emerging sector. 

Specific results 

Advanced therapies are currently regulated in two ways in the countries studied under this service contract.  

In  Canada,  the  USA  and  South  Korea  most  advanced  therapies  are  formally  regulated  as  medicinal 

products (biologics), although consideration is given to the specific characteristics of advanced therapies in 

the  framework  of  the  individual  decision-making  procedure  for  marketing  authorisation,  often  in  close 

consultation with the developers. 

Given that the regulatory frameworks in these three countries are largely similar, differences in research 

activities  are  not  considered  to  be  a  direct  outcome  of  regulatory  framework  differences  but  most  likely 

stem  from  other  characteristics  of  the  innovation  system  for  advanced  therapies  in  each  of  the  selected 

countries. However, the assessment of these characteristics was beyond the scope of this study. 

Japan has put in place a specific regulatory framework for advanced therapies. However, as it entered into 

force only recently, it is difficult to measure its impact on advanced therapies. 

The final report with all the findings is available on the website of DG SANTE42. 

3. SERVICE  CONTRACT:  Organisation  of  a  workshop 
targeting  media,  civil  society  and  health  professionals 
relating to the implementation of the Decision 1082/2013/EU 
on  serious  cross-  border  threats  to  health;  and  to  conduct  a 
study on the availability/supply capacities of critical medical 
countermeasures  at  Member  State  level  and  in  the  industry 
and  to  organise  an  inter-sectoral  table  top  exercise  on 

42 https://ec.europa.eu/health/sites/health/files/human-use/docs/20147306_rfs_chafea_2014_health_24_060516.pdf 

23 

 
 
 
                                                      
outbreak  coordination  and  response  involving  public  health 
and other sectors 

Background information 

The service contract's aim was to support the implementation of Decision 1082/2013/EU on serious cross-
border threats to health43, which covers several health security areas. 

The  CELESTE  consortium  led  by  Public  Health  England  and  including  the  Swedish  Defence  Agency, 

Umea University (Sweden) and Istituto Superiore di Sanita (Italy), signed a contract to carry out two tasks:  

1)  organise  a  workshop  ‘targeting  media,  civil  society  and  health  professionals  relating  to  the 

implementation of the Decision 1082/2013/EU on serious cross-border threats to health’; and  

2)  conduct  a  study  on  the  ‘availability/supply  capacities  of  critical  medical  countermeasures  at 

Member  States  level  and  in  the  industry  and  to  organise  an  inter-sectoral  table  to  exercise  on 

outbreak coordination and response involving public health and other sectors’. The contract ran for 

7 months starting in December 2015 and had a maximum price of EUR 585 612. 

Brief description 

The  contractor  organised  a  workshop  for  media,  civil  society  and  health  professionals  on  the 

implementation  of  the  serious  cross-border  health  threats  decision  (Decision  1082/2013/EU).  The 

workshop aimed to identify ways to ensure consistent and professional risk and crisis communication with 

the  public  and  stakeholders,  in  support  of  the  work  of  the  Health  Security  Committee  Communicators’ 

Network.  There  were  participants  from  21  EU  Member  States  and  Norway  with  a  crisis  communication 

background in a health setting, nine journalists and one civil society organisation (the European Federation 

of Nurses Association) active in the field of public health. There were also participants from DG SANTE, 

Chafea, ECDC and WHO. 

The  study  identified  needs  for  medical  counter  measures  in  the  framework  of  the  serious  cross-border 

health  threats  decision.  It  also  identified  conditions  under  which  Member  States  could  use  the  joint 

procurement  mechanism  for  medical  countermeasures  against  serious  cross-border  health  threats  to 

improve  their  preparedness.  Similarly,  it  assessed  the  feasibility  and  willingness  of  Member  States  to 

jointly  procure  such  medical  countermeasures.  The  contractor  also  organised  a  table  top  exercise  on 

43https://ec.europa.eu/health/sites/health/files/preparedness_response/docs/decision_serious_crossborder_threats_22102013_en.pdf 

24 

 
 
 
 
                                                      
climate change and serious cross-border threats to health involving public health players and specialists in  

other sectors. 

This inter-sectoral table top exercise, called 'Orion', explored the potential challenges of climate change for 

the EU. Its main purpose was to bring together public health and environmental/climate change specialists 

to improve the crisis response to climate change-related public health threats affecting EU countries and 

agencies. The scientific evidence base was considered to be important for informing decision making and 

linking it to climate-focused research. Participants included representatives from public health bodies and 

environmental/climate  change  specialists  from  21  EU  Member  States  and  Iceland.  There  were  also 

participants from DG SANTE, ECDC, DG CLIMA and WHO. 

Specific results 

The study's outcomes generally supported the Commission's ongoing work and specifically the pursuit of 

the Joint Procurement Agreement.  

The  workshop  identified  several  key  themes  for  the  way  forward,  namely:  (i)  more  training  on 

communicating with all groups involved in crisis communication; (ii) clearer policy and procedures; and 

(iii)  a  common  database  of  templates,  plans  and  tools  that  could  be  used  for  the  planning  and  response 

phases of an incident.  

The  table top exercise  highlighted  several  challenges,  particularly  the  need  to  increase collaboration  and 

strengthen  inter-sectoral  coordination  and  the  need  for  specific  communication  strategies  and  standard 

operating procedures for climate change. The exercise also led to specific recommendations on developing 

EU  guidelines  to  support  the  disinfection  of  aircraft  and  developing  an  early  warning  and  response 

(EWRS) type system that would include the reporting of all hazards (N.B. this has now been implemented). 

This wide-ranging exercise was a unique opportunity to gather EU Member States to discuss the climate 

change challenge and to produce a series of constructive recommendations. 

4. SERVICE  CONTRACT:  Organisation  of  a  command  post 
exercise  on  serious  cross-border  threats  to  health  falling 
under the chemical and environmental categories 

Background information 

The  CELESTE  consortium  led  by  Public  Health  England  and  including  the  Swedish  Defence  Agency, 

Umea  University  (Sweden)  and  Istituto  Superiore  di  Sanita  (Italy),  signed  a  contract  to  organise  a 

25 

 
 
 
command  post  exercise  on  chemical  and  environment-related  serious  cross-border  health  threats.  The 

contract ran for 12 months from January 2015 and had a maximum price of EUR 458, 988. 

The command post exercise aimed to provide EU Member States, European Agencies and other interested 

organisations with an opportunity to test the adequacy of existing plans, systems, communication processes 

and  tools  to  meet  the  requirements  of  the  decision  on  serious  cross-border  health  threats  (Decision 
1082/2013/EU)44. The decision applies to all 28 EU Member States and sets out an ‘all hazards’ approach 

for alerting a public health emergency of international concern that includes serious cross-border threats to 

health from biological, chemical, environmental events and evens of unknown origin. 

The  command  post  exercise,  called  'Quicksilver  Plus',  took  place  over  2  days.  Participants  included 

representatives from the public health and chemical sectors and communication specialists from the Health 

Security  Committee  Communicators’  Network.  15  EU  Member  States  and  1  EEA  country  (Norway) 

participated  in  the  exercise  along  with  participants  from  ECDC,  WHO,  DG  SANTE,  DG  HOME,  DG 

ECHO and the Joint Research Centre. 

The 'Quicksilver Plus' exercise built on the 'Quicksilver' exercise organised in 2013. It helped participants 

increase  their  understanding  of  the  different  roles  and  responsibilities  in  the  strategic  management  of 

chemical and environment-related cross-border events and improve their preparedness and resilience. 

Specific results: 

The main strategic findings from 'Quicksilver' were: 

- 

further  EU-wide  education  and  training  is  needed  to  ensure  stakeholders  fully  understand  the 

decision's impact and requirements; 

- 

the process for the prompt sharing of information between the relevant EU and national institutions 

needs to be improved to ensure rapid risk assessment and crisis communication; and 

- 

the  Health  Security  Committee  Communicator’s  Network  needs  to  be  further  developed  and 

awareness of its role and responsibilities needs to be increased. 

The  'Quicksilver  Plus'  exercise  provided  strong  evidence  that  good  progress  had  been  made  in  all  these 

areas and highlighted the following key areas for continued improvement: 

-  The Health Security Committee’s strategic role to provide situational awareness and to coordinate 

the  cross-border  response  to  public  health  incidents.  A  standard  situational  awareness  template 

could be used to ensure a common understanding between Member States and the Commission.  

44https://ec.europa.eu/health/sites/health/files/preparedness_response/docs/decision_serious_crossborder_threats_22102013_en.pdf 

26 

 
 
                                                      
-  Some Member States should consider reviewing their structures and capacities across all sectors to 

align with the serious cross-border health threats decision and to further increase their awareness of 

International Health Regulations, including their in-country reporting processes. 

Feedback  confirmed  that  most  participants  agreed  that  the  exercise  allowed  them  to  practise  their 

emergency role and to use supporting documents and tools. It also helped them understand their role and 

responsibilities during an emergency and increased their knowledge of the response concept, structure and 

procedures. 

5. SERVICE  CONTRACT:  Support  of  the  implementation  of 
Decision  1082/2013/EU  especially  as  regards  preparedness 
and response activities in the context of the Ebola  Epidemic 
in  West  Africa,  in  particular  the  organisation  of  four 
workshops  to  be  embedded  as  parallel  sessions 
in  a 
Commission organised conference 

Background information 

The  CELESTE  consortium  led  by  Public  Health  England  and  including  the  Swedish  Defence  Agency, 

Umea  University  (Sweden),  and  Istituto  Superiore  di  Sanita  (Italy),  signed  a  contract  to  support  the 

implementation  of  the  serious  cross-border  health  threats  decision  (Decision  1082/2013/EU)  especially 

preparedness and response activities in the context of the Ebola epidemic in West Africa. Its role was to 

organise four workshops in the form of parallel sessions in a conference organised by the Commission. The 

contract ran for 10 months from April 2015 and had a maximum price of EUR 499 719. 

Brief description 

DG  SANTE,  together  with  the  Luxembourg  Presidency,  organised  a  conference  on  ‘lessons  learned  for 

public health from the Ebola outbreak in West Africa — how to improve preparedness and response in the 

EU for future outbreaks’. The aim of this conference was to identify learning points arising from the Ebola 

epidemic  which  are  crucial  to  strengthen  health  security  in  the  EU,  better  prepare  for  similar  crises  and 

ensure that the EU can respond rapidly, flexibly and effectively to emergencies and disease outbreaks in 

the future. 

27 

 
 
 
 
 
The  conference  gathered  over  350  participants  from  health  authorities,  EU  bodies,  international 

organisations and NGOs. It included national experts, organisers of projects on risk and crisis management 

and communicators involved in the outbreak response in West Africa and the preparedness and response in 

the EU. 

The conference included four parallel workshops on different aspects of the Ebola crisis: 

-  The Ebola outbreak as a complex crisis: the EU response and inter-sectoral cooperation 

-  Good practices and innovation for pre-clinical and clinical management of Ebola virus disease 

-  Communication activities addressed to the public and health professionals 

-  The EU preparedness and response planning as part of global health security 

Brief description 

Considerations and recommendations generated by the four workshops include: 

1.  A peer review mechanism could help Member States improve their national preparedness plans 

taking  into  account  past  and  current  initiatives  on  independent  country  evaluations  at  global 

and regional level. 

2.  Article 17 of the serious cross-border health threats decision (Decision 1082/2013/EU)45on the 

coordination of the Health Security Committee should contribute to a stronger decision making 

and to a reinforced strategic response. 

3.  The  Joint  Procurement  Agreement  needs  to  be  further  developed  and  mechanisms  for  its 

effective  use  —  involving  relevant  training  exercises  —  during  an  ongoing  emergency 

situation needs to be explored. 

4.  State-of-the-art capacity for airborne medical evacuation (Medevac) and ground transportation 

in Europe requires a shared and long-term financial commitment of countries and international 

institutions. 

5.  Infection prevention and control standards need to be put in place before an emergency from 

an  infectious  disease  of  high  impact  (IDHI)  occurs.  This  applies  in  particular  to  critical 

structures such as emergency departments or intensive care units. 

45https://ec.europa.eu/health/sites/health/files/preparedness_response/docs/decision_serious_crossborder_threats_22102013_en.pdf 

28 

 
 
 
 
 
 
                                                      
6.  Global collaboration and funding in research is needed to develop a strategic plan for globally 

coordinated research and development for IDHI that encompasses inter-epidemic and epidemic 

clinical epidemiology, vaccine and drug development, diagnostic standardisation, and personal 

protective equipment. 

7.  Possibilities for joint communications between EU/EEA Member States, the EU, civil society 

and  key  stakeholders  (such  as  NGOs  and  health  professionals’  organisations)  to  more 

systematically communicate must be explored. 

8.  The  EU  capacity  to  prepare  and  respond  to  emergencies  with  a  public  health  implication 

should  be  strengthened  by  operationalising  the  European  Medical  Corps,  as  part  of  the 

European emergency response capacity under the EU Civil Protection Mechanism, and of the 

Global Health Emergency Workforce and other such bodies. 

The  conference's  recommendations  were  forwarded  to  the  Health  Council  of  December  2015.  These 

recommendations contributed to EU and national preparedness activities in the following years. 

Information on the conference is available on DG SANTE’s website46. 

6. SERVICE  CONTRACT:  Study  on  the  mapping  of  best 
testing  methods  and 
practices  and  development  of 
procedures for identifying characterising flavours in tobacco 
products 

Background information 

A Consortium led by the Dutch National Institute for Public Health and the Environment (RIVM) carried 

out the study to map best practices and develop testing methods and procedures to identify characterising 

46 https://ec.europa.eu/health/preparedness_response/events/ev_20151012_en 

29 

 
 
 
 
 
 
 
 
 
 
                                                      
flavours in tobacco products. The contract ran for 11 months from August 2014 and had a maximum price 

of EUR 195 400. (The study was published in the second half of 2016.) 

Brief description 

The main purpose was to help the Commission implement the newly revised Tobacco Product Directive47, 

specifically to determine whether a tobacco product has a characterising flavour and to set maximum levels 

for additives or combinations of additives that cause the characterising flavour. 

The study presented the most suitable method/s to decide whether a tobacco product has a characterising 

flavour other than tobacco. It also developed, based on a number of pilot tests, all documentation necessary 

to replicate the study, including comprehensive protocols and standard operating procedures for each step 

of  the  procedure  and/or  activity.  It  also  provided  a  basis  for  establishing  and  operating  an  independent 
advisory panel, as referred to in the Tobacco Product Directive II48. 

Specific results 

This study  produced  a  new  method,  combining  sensory  tests and chemical  analyses, to  assess  whether a 

tobacco product has a flavour other than tobacco. 

This new method involves experts who assess tobacco products by smelling them, focusing on detecting 

attractive flavours such as cherry, menthol or vanilla, or similar. This step is followed by a robust chemical 

analysis that determines any flavours. With this approach, authorities can better determine whether tobacco 

products placed on the EU market comply with the Directive’s rules. 

The  study's  results  helped  the  Commission  draft  rules  and  procedures49  to  determine  whether 

tobacco products  have  a  characterising  flavour  and  provided  a  scientific  basis  for  the  work  of  the 

Independent Advisory Panel and the Technical Group of sensory and chemical assessors. 

The final report is available on DG SANTE’s website50. 

47 https://ec.europa.eu/health/tobacco/products/revision_en 

48 https://ec.europa.eu/health/sites/health/files/tobacco/docs/dir_201440_en.pdf 

49 https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2016.131.01.0048.01.ENG&toc=OJ:L:2016:131:TOC 

50 https://ec.europa.eu/health/sites/health/files/tobacco/docs/hetoc_frep_en.pdf 

30 

 
 
 
                                                      
7. SERVICE CONTRACT: Assessment of citizens’  exposure to 

tobacco marketing 

Background information 

A Consortium led by Burson-Marsteller s.p.r.l carried out an assessment of citizens’ exposure to tobacco 

marketing over 10 months (from September 2014 to July 2015) for a maximum price of EUR 199 950. 

Brief description 

The  assessment  report  gives  the  Commission  a  comprehensive  overview  of  channels  through  which  EU 

citizens, and in particular young people, are exposed to the marketing of tobacco products and e-cigarettes. 

The  marketing  of  tobacco  products  is  addressed  by  EU  legislation  and  recommendations  such  as  the 
Tobacco  Advertising  Directive  (2003/33/EC),  the  Audio-visual  Media  Service  Directive  2010/13/EU51 

(AVMSD)  (which  replaced  the Television  Without Frontiers  Directive  97/36/EC),  the Tobacco  Products 
Directive 2014/40/EU52 and the Council Recommendation on the prevention of smoking and on initiatives 
to improve tobacco control (2003/54/EC)53.  In addition, the EU and its Member States are parties to the 
WHO Framework Convention on Tobacco Control54 (FCTC), adopted in 2003, which includes articles and 

guidelines on the advertising, promotion and sponsorship of tobacco products. Individual Member States 

also have  laws banning  various  forms  of  tobacco  advertising,  although  their  extent  and  scope  vary  from 

country to country. 

Specific results 

The study investigated the reality of tobacco advertising and marketing in a representative sample of EU 

Member  States.  The  detailed  evidence  provided  in  the  report  (which  is  available  on  DG  SANTE’s 
website55)  sheds  light  on  how  current  EU  and  national  laws  on  tobacco  and  e-cigarette  advertising  are 

working in practice. 

51 https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A32010L0013 

52 https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ%3AJOL_2014_127_R_0001 

53 https://eur-lex.europa.eu/legal-content/en/TXT/?uri=CELEX:32003.0054 

54http://apps.who.int/iris/bitstream/handle/10665/42811/9241591013.pdf;jsessionid=2A5B92E5740040389E29FCC238FAD72E?s
equence=1 

55 https://ec.europa.eu/health/sites/health/files/tobacco/docs/citizensexposure_tobaccomarketing_en.pdf 

31 

 
 
 
 
                                                      
8. SERVICE  CONTRACT:  Study  on  the  identification  of 
potential  risks  to  public  health  associated  with  the  use  of 
refillable  electronic  cigarettes  and  on  the  development  of 
technical specifications for refill mechanisms — PRECISE 

Background information 

The  European  Regulatory  Science  on  Tobacco  (EUREST)  Consortium  led  by  the  Biomedical  Research 

Foundation of the Academy of Athens (BRFAA) in  partnership with the European Network on Smoking 

and Tobacco Prevention (ENSP) carried out a study to identify potential public health risks associated with 

the use of refillable electronic cigarettes and to develop technical specifications for refill mechanisms. The 

contract  ran  for  10  months  (from  December  2014  to  October  2015)  and  had  a  maximum  price  of 

EUR 180 450. 

Brief description 

The  PRECISE  study  (Potential  Risks  from  Electronic  Cigarettes  &  their  technical  Specifications  in 

Europe)  aimed  to  provide  the  Commission  with  an  overview  of  potential  public  health  risks  associated 

with  the  use  of  refillable  electronic  cigarettes  and  with  information  on  technical  specifications  for  refill 

mechanisms. 

Specific results 

The study had several interesting and tangible results: 

1. The study provides an overview of the EU e-cigarette market, focusing on refillable e-cigarettes, based 

on a sample of EU Member States. For each of these Member States, a comprehensive evaluation of the 

most popular products on the market was conducted and a number of samples were purchased for further 

evaluation.  The  study  also  identified  and  assessed  public  health  risks  associated  with  the  use  of 

e-cigarettes, particularly refillable e-cigarettes. 

2.  The  study  identifies  the  technical  specifications  for  refill  mechanisms,  based  on  the  aforementioned 

risks,  stakeholder  feedback,  European  standards  already  in  place  and  the  evaluation  of  the  purchased 

samples.  Design  features  were  identified  that  may  limit  the  risks  associated  with  the  refilling  processes, 

and may also address requirements that e-cigarettes do not leak and are child- and tamper-proof, thereby 

protecting both users and non-users, especially children. 

32 

 
 
 
The  study's  results  helped  the  Commission  draft  the  technical  standards  for  the  refill  mechanism  of 
electronic cigarettes (Commission Implementing Decision (EU) 2016/58656) and to prepare its report to the 

European  Parliament  and  the  Council  on  the  potential  risks  to  public  health  associated  with  the  use  of 
refillable electronic cigarettes (Commission Report COM(2016) 26957). 

The study is available on DG SANTE’s website58. 

HIGHLIGHTS  OF  CO-FUNDED 

‘CROSS-CUTTING’  AND 

‘OTHER’ ACTIONS 

1. Dissemination activities carried out in 2016 

In 2016, a number of dissemination activities were carried out to promote the health programme's results. 
These included: 

  As in previous years, Chafea disseminated the results of EU co-financed actions electronically or at 

conferences  and  other  meetings  attended  by  relevant  stakeholders.  The  Agency  produced 

publications  highlighting  the  health  programme's  achievements  and  value  for  money,  e.g.  fact 

sheets and brochures that illustrate that EU action can complement or stimulate other actions or fill 

in  gaps,  e.g.  at  Member  State  level.  Chafea  organises  or  participates  in  a  range  of  ad  hoc 

information and dissemination activities. 

  A revamped health programme project database was developed and launched. This comprehensive, 

user-friendly database, maintained by Chafea, makes EU health programme deliverables available 

to the public for consultation or further use.  

 

In 2016, Chafea published brochures on: (i) rare diseases59, (ii) health security60. 

56https://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=uriserv%3AOJ.L_.2016.101.01.0015.01.ENG&toc=OJ%3AL%3A2016 %3A101 %3ATOC 

57 https://ec.europa.eu/transparency/regdoc/rep/1/2016/EN/1-2016-269-EN-F1-1.PDF 

58 https://ec.europa.eu/health/sites/health/files/tobacco/docs/potentialrisks_specs_refillableecigarettes.pdf 

59 https://publications.europa.eu/en/publication-detail/-/publication/fd1f05fc-6def-11e8-9483-
01aa75ed71a1/language-
en?WT.mc_id=Selectedpublications&WT.ria_c=19980&WT.ria_f=3170&WT.ria_ev=search 

60 https://publications.europa.eu/en/publication-detail/-/publication/13b6f22d-75e4-11e8-ac6a-
01aa75ed71a1/language-
en?WT.mc_id=Selectedpublications&WT.ria_c=19980&WT.ria_f=3170&WT.ria_ev=search 

33 

 
 
                                                      
  The  Agency  also  began  work  to  produce  additional  brochures  in  2017,  in  a  single  request  for 

service  together  with  13  info  sheets  covering  several  of  the  health  programme's  thematic 
priorities61. 

In  addition,  Chafea  continued  to  disseminate  the  health  programme's  results  at  national,  EU-wide  and 

international  events.  It  ensured  that info sheets  on  health  programme  actions  on  specific  themes  such as 

chronic diseases, HIV and health security were disseminated in at least three EU languages at such events. 

The  Agency’s  pop-up  stand  and  handouts  were  present  at  more  than  15  national  or  EU-level  events, 

including at these major events: 

1.  A two-day conference on migrants' health, organised in May 2016 in close cooperation with DG 

SANTE,  the  Portuguese  Directorate-General  of  Health,  the  International  Organisation  for 

Migration  and  the  COST  ADAPT  expert  network.  This  conference  brought  together  165 

participants, mainly policy makers and experts from 25 EU countries. 

2.  More than 10 workshops at major conferences such as: 

 

 

 

 

 

the high level conference on global health security; 

the 16th international conference on integrated care (ICIC 2016); 

the 19th European Health Forum Gastein; 

'Demographics and Diversity in Europe'; and 

the 9th European Public Health conference (EPH2016). 

Chafea also organised a cluster meeting on nutrition and physical activity in Budapest from 30 November 

to  2  December.  This  event  brought  together  90  participants,  including  journalists,  policy  makers,  health 

and  education  authorities,  community  and  experts,  representatives  of  the  WHO  and  the  Commission.  It 

comprised eight sessions and 40 presentations. 

2. Other actions 

Scientific Committees 
When preparing policies and proposals on consumer safety, health and the environment, the Commission 

relies  on  independent  scientific  committees  for  sound  scientific  advice  and  for  information  on  new  and 

emerging problems. 

61 http://ec.europa.eu/chafea/health/bookshelf/infosheets/index_en.htm 

34 

 
 
 
 
                                                      
Between  April  2013  and  March  2016,  three  committees  provided  scientifically  sound  advice  for  policy 

makers to ensure a high level of consumer safety, health and environmental protection that citizens expect 

from the EU. 

These committees were: 

  Scientific Committee on Consumer Safety (SCCS) 

  Scientific Committee on Health and Environmental Risks (SCHER) 

  Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) 

The following two Scientific Committees, established by the Commission Decision C(2015)538362, started 
a new five-year term in April 2016 that runs until March 2021: 

  Scientific Committee on Consumer Safety (SCCS)63 

 

 Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) 

Only  the  SCENIHR  and  SCHER  and  later  their  successor  the  Scientific  Committee  on  Health, 
Environmental and Emerging Risks (SCHEER) were financed by the health programme. 

Key figures on SCHEER's activities between April and December 201664 include: 

  2 SCHEER documents adopted (scientific opinions, scientific advice and statements): 

o  Opinion  on  biological  effects  of  ultraviolet  radiation  relevant  to  health  with  particular 

reference to sunbeds for cosmetic purposes65 

o  Opinion on additives used in tobacco products (Tobacco additives II)66 

  45 meeting days organised in Luxembourg (including external meetings) 

  5 scientific articles published in scientific journals67 

62 https://ec.europa.eu/health/scientific_committees/docs/call_2015_5383_decision_with_annexes_en.pdf 

63 https://ec.europa.eu/health/scientific_committees/consumer_safety_en 

64 From April 2016 (the start of the Scientific Committee's new term) to December 2016. 
65 https://ec.europa.eu/health/sites/health/files/scientific_committees/scheer/docs/scheer_o_003.pdf 

66 https://ec.europa.eu/health/scientific_committees/consultations/public_consultations/scenihr_consultation_29_en 

35 

 
 
 
 
 
 
 
 
 
                                                      
  1 Health-EU newsletter edition dedicated to the activities of the Scientific Committees 

  The amount spent on all the activities was EUR 471 381.41: 

o  EUR 345 221.4168 for producing Opinions and for meetings; and 

o  EUR 126 160  for  technical  assistance  (literature  search,  editing  of  opinions,  website 

mastering, assistance for the Health-EU newsletter, dissemination activities). 

As of April 2016, the committees' expenditure included EUR 38 158 for SCENIHR (for one final opinion) 
and EUR 4 835 for SCHER (for two final opinions and one guidance document). 

Expert panel on effective ways of investing in health 

The expert panel on effective ways of investing in health is an interdisciplinary and independent group 

established  by  the  Commission to  provide  non-binding  advice  on  matters  related  to  effective,  accessible 

and resilient health systems. 

The creation of the panel stems from the June 2011 Council conclusions on  health systems, in which the 

European  Commission  was  invited  to  initiate  a  process  for  independent  and  evidence-based  advice  on 

health systems to support policy making on health. Since starting its activities on 11 July 2013, the expert 

panel  has  been  working  consistently  on  topical  questions  issued  by  the  Commission.  The  expert  panel's 

opinions  are  the  views  of  its  independent  scientists  and  do  not  necessarily  reflect  the  views  of  the 

Commission. 

The  expert  panel's  areas  of  competence  include,  but  are  not  limited  to,  primary  care,  hospital  care, 

pharmaceuticals,  research  and  development,  disease  prevention  and  health  promotion,  social  protection, 

cross-border cooperation, health economics, eHealth and health education and literacy. 

The expert panel delivers opinions, which can support health policy making in the EU. These opinions are 

for the consideration of the Member States’ governments and authorities in charge of delivering healthcare. 

They are also for the consideration of various stakeholders. They aim to generate discussions at EU and 

67 https://www.sciencedirect.com/science/article/pii/S0167779916300324 
 https://www.sciencedirect.com/science/article/pii/S0273230016301970 
 https://www.sciencedirect.com/science/article/pii/S0273230016300149 
 https://www.sciencedirect.com/science/article/pii/S0273230015301501 
 https://www.sciencedirect.com/science/article/pii/S0273230016300137 
68  This  includes  travelling,  accommodation,  daily  allowances  and  special  indemnities.  In  2016,  travelling, 
accommodation and daily allowances were paid under the administrative budget (representing EUR 148 186.41) and 
special  indemnities  were  paid  under  the  health  programme  and  the  consumer  programme  (representing 
EUR 197 035). 

36 

 
 
 
 
 
                                                                                                                                                                             
national level to inform policymaking. They all focus on the added value of working at EU level in terms 

of mutual learning, identifying best practice and sharing knowledge. 

The expert panel produced the following opinions in 2016: 

  Typology of health policy reforms and framework for evaluating reform effects69 

  Best practices and potential pitfalls in public health sector commissioning from private providers70 

  Memorandum — Reflections on hospital reforms in the EU71 

  Access to health services in the European Union72 

  Disruptive Innovation. Considerations for health and health care in Europe73 

The panel's first three-year term ended in May 2016. The renewed panel of 14 members was appointed in 

November 2016 for a three-year term that will run until May 2019. 

69 https://ec.europa.eu/health/expert_panel/sites/expertpanel/files/013_healthpolicyreforms_reformeffects_en.pdf 

70 https://ec.europa.eu/health/expert_panel/sites/expertpanel/files/docsdir/014_publichealthsector_privateproviders_en.pdf 

71 https://ec.europa.eu/health/expert_panel/sites/expertpanel/files/016_memorandum_hospitalreforms_en.pdf 

72 https://ec.europa.eu/health/expert_panel/sites/expertpanel/files/015_access_healthservices_en.pdf 

73 https://ec.europa.eu/health/expert_panel/sites/expertpanel/files/015_access_healthservices_en.pdf 

37 

 
 
 
                                                      
IMPLEMENTATION OF ANNUAL WORK PROGRAMME 2016 

CALLS FOR PROPOSALS 

Calls  for  proposals  for  projects  and  operating  grants  actions  were  launched  on  4  March 2016  on  the 
Horizon 2020 programme's participants' portal74, on the public health website on Europa75 and on Chafea’s 
website76. Most applications came from the main partners (i.e. coordinators of the submitted proposals) in 

the  EU-15  Member  States.  These  accounted  for  68%  of  project  applications,  100%  of  operating  grant 

applications  and  100%  of  joint  action  applications.  The  percentage  of  partners  from  new  EU  Member 

States involved in the joint actions is 46.4% of all partners, whereas for projects it is 39.1%. 

Chafea organised a workshop on joint actions in July 2016 and a joint action quality assurance workshop in 

November 2016. In addition, the health programme's national focal points organised national information 

days  throughout  April  and  May  2016.  Guidelines  for  applying  were  made  available  on  the  participants' 

portal. Chafea's helpdesk also provided practical assistance. 

A total of 81 project proposals including the ERNs and 13 operating grant proposals were received with a 

total  requested  budget  of  EUR  60 904 730.37.  The  available  annual  budget  for  these  two  categories  of 

funding mechanism, however, was EUR 17 850 000. Eight of the project proposals were ineligible and 27 

of the 73 remaining applications ended up being funded (37 %) and 46 being rejected. Applications were 
evaluated according to the rules and criteria set out in the annual work programme for 2016 (AWP 2016)77 

and  in  the  calls for  proposals. 23  external  experts from  13  countries  took  part  in  the  evaluation  process. 

They were drawn from a list that was established following a call for expressions of interest entitled ‘call 
for expressions of interest in the area of public health’78. 

The evaluation process had two stages: 

In  the  first  stage,  three  external evaluators reviewed each  proposal  and  a  consolidated  evaluation  report 

was drawn up for each proposal at a consensus meeting organised by Chafea. 

74http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/3hp/index.html#c,calls=hasForthcomingTo
pics/t/true/0/1/0&hasOpenTopics/t/true/0/1/0&allClosedTopics/t/true/1/1/0&+PublicationDate/desc 
75 https://ec.europa.eu/health/funding/programme_en 
76 http://ec.europa.eu/CHAFEA/health/index.html 
77 Commission Implementing Decision C (2014) 3383 
78 OJ S 040-065407, 26.2.2014 and http://ec.europa.eu/CHAFEA/ami/. 

38 

 
 
 
 
                                                      
In the second stage, the evaluation committee checked that the evaluators had complied with the relevant 

rules and criteria. It then drew up final lists of proposals recommended for funding, together with reserve 

lists. The evaluation committee comprised representatives from DG SANTE, the Directorate-General for 
Research and Innovation (DG RTD) and from Chafea. The award decisions for 14 projects79, 13 operating 
grants80 and 23 European Reference Networks (ERNs)81 were taken by Chafea. 

Project grants 

Project grants were awarded to actions involving several partners, usually public health bodies and NGOs. 

The maximum EU contribution is 60% of the eligible costs. However, it may go up to 80% if a proposal 

meets the criteria for 'exceptional utility'. In 2016, two projects qualified for exceptional utility: MyHealth 

and ORAMMA 

In  total,  81  proposals  were  submitted  to  the  call  for  proposals  for  projects.  Of  these,  12  proposals  were 

recommended for funding and 16 were placed on a reserve list. In the end, 14 projects were funded for a 

total of EUR 8 795 212.04. Their distribution among the programme objectives was as follows: 

1.  Health promotion: EUR 6 266 372.65 (8 projects) 

2.  Health threats: no project call 

3.  Health systems: no project call 

4.  Better and safer healthcare: EUR 2 528 839.39 (6 projects) 

The below table lists all projects funded per objective and thematic priority. 

Financial instrument  Chafea project grants by objective  
Objective: 
Description 
objective: 

1 
To  promote  health,  prevent  diseases  and  foster 
supportive  environments  for  healthy 
lifestyles 
taking  into  account  the  ‘health  in  all  policies’ 
principle. 

the 

of 

Thematic priority: 

1.1  Cost-effective  promotion  and  prevention 
measures in line, in particular, with EU strategies on 
alcohol and nutrition 

User reference 

Project title 

Amount 
committed  in 
EUR 

79 http://ec.europa.eu/chafea/health/funding/calls-for-tenders/documents/grants-projects-awarded-2016_en_en.pdf 
80 http://ec.europa.eu/chafea/health/funding/calls-for-tenders/documents/operating-grants-awarded-2016_en_en.pdf 
81 http://ec.europa.eu/chafea/health/funding/calls-for-tenders/documents/grants-ern-awarded-2016_en_en.pdf. 

39 

 
 
 
 
 
 
                                                      
738055  —  Localise  It 
— PJ-02-2016 

Local  Strategies  to  Reduce  Underage  and  Heavy 
Episodic Drinking 

745 979.00 

738091  —  MyHealth 
— PJ-01-2016 

Models 
to  Engage  Vulnerable  Migrants  and 
Refugees  in  their  Health,  through  Community 
Empowerment and Learning Alliance 

1 134 547.95 

738148  —  ORAMMA 
— PJ-01-2016 

Operational  Refugee 
Approach 

and  Migrant  Maternal 

477 014.37 

Focus on Youth, Football and Alcohol 

552 168.45 

Strengthen  Community-based  Care  to  Minimise 
Health Inequalities and Improve The Integration of 
Vulnerable  Migrants  and  Refugees  Into  Local 
Communities 

872 602.67 

738157 — F.Y.F.A. — 
PJ-02-2016 

738186  —  Mig-
HealthCare  —  PJ-01-
2016 

Total 
Thematic priority: 

User reference 

738162  —  EPPIC  — 
PJ-03-2016 
Total 
Thematic priority: 

User reference 

— 
738127 
EFFICHRONIC  — 
PJ-04-2016 

738202  —  SEFAC  — 
PJ-04-2016 
Total 
Objective: 
Description 
objective: 
Thematic priority: 

of 

User reference 

1.2  Measures  to  complement  the  Member  States’ 
action in reducing drug-related health damage 
Project title 

Exchanging  Prevention  Practices  on  Polydrug  Use 
Among Youth in Criminal Justice Systems 

1.4  Support  cooperation  and  networking  in  the  EU 
in relation to preventing and improving the response 
to chronic diseases 
Project title 

Enhancing  Health  Systems  Sustainability  by 
Providing Cost-Efficiency Data of Evidenced Based 
Interventions for Chronic Management in Stratified 
Population 
Social  Engagement  Framework  for  Addressing  the 
Chronic Disease Challenge 

4 
To facilitate access to better and safer healthcare for 
EU citizens. 
4.2  Coordinated  action  at  EU  level  in  order  to 
effectively help patients affected by rare diseases 
Project title 

3 782 312.44 

Amount 
committed  in 
EUR 
599 511.79 

599 511.79 

Amount 
committed  in 
EUR 
984 620.43 

899 927.99 

1 884 548.42 

Amount 
committed  in 
EUR 
549 478.34 

Transfusion  and  Transplantation:  Protection  and 
Selection of Donors 

738145 
— 
TRANSPOSE  —  PJ-
05-2016 
777215  —  EuRRECa 
— PJ-06-2016 
777259  —  U-IMD  —  Unified  European  Registry  for  Inherited  Metabolic  398 138.23 

European Registries for Rare Endocrine Conditions 

398 768.67 

40 

 
 
 
 
 
 
 
 
 
 
— 

PJ-06-2016 
777295 
REGISTRY 
WAREHOUSE — PJ-
06-2016 
777304  —  ERK-REG 
— PJ-06-2016 
777336  —  PARTNER 
— PJ-06-2016 
Total 
Chafea 
PROJECTS 

TOTAL 

Disorders 
Registry for Rare diseases Data Warehouse 

401 904.83 

Registry for Rare Kidney Diseases 

Registry for Paediatric Rare Tumours 

380 564.32 

399 985.00 

2 528 839.39 
8 795 212.04 

European Reference Networks (sole beneficiary grants) 

Each  European  Reference  Networks  (ERN)  had  to  submit  a  proposal  in  order  to  be  assessed  by  the 
independent assessment bodies (IABs) and become an approved ERN. Following the decision of the Board 
of  Member  States,  each  ERN  also  submitted  a  proposal  for  a  framework  partnership  agreement  (FPA), 
together with their specific grant agreement (SGA) proposal for their first year of operation. 

Once the decision of the Board of Member States was taken and the 23 networks approved, Chafea invited 
them to participate in the grant agreement preparation phase, so that the related FPAs and SGAs could be 
signed as quickly as possible in the year N+1. 

According  to  the  financing  decision,  each  network  could  receive  up  to  EUR 200 000.  However,  not  all 
networks requested the full available amount. The amount of co-funding awarded to them is in the table 
below. 

Financial instrument 

Chafea ERN SGAs under FPA by objective 

Objective: 
Description of objective:  To facilitate access to better and safer healthcare for 

4 

EU citizens. 

Thematic priority: 

4.1  Support  the  establishment  of  a  system  of 
European  Reference  Networks  for  patients  with 
conditions requiring highly specialised care 

User reference 

Name of ERN 

Amount 
committed  in 
EUR 
200 000.00 

767231 — ERN-RND — 
ERN-SGA-2016 

768967  — 
ERN-
PAEDCAN  —  ERN-
SGA-2016 
768985  —  ERKNet  — 
ERN-SGA-2016 

ERN Rare Neurological Diseases 

ERN Paediatric Cancer 

200 000.00 

ERN Rare Kidney Disease Reference Network 

199 645.00 

41 

 
 
 
 
 
 
 
 
 
768989  —  ERN-NMD 
— ERN-SGA-2016 

768995  — 
ERN 
GENTURIS  —  ERN-
SGA-2016 
769001  —  ERN-SKIN 
— ERN-SGA-2016 

ERN 
769015  — 
HEART  —  ERN-SGA-
2016 
769019  — 
ERN-
RECONNET  —  ERN-
SGA-2016 

769029  —  EURACAN 
— ERN-SGA-2016 

769031  —  Endo-ERN 
— ERN-SGA-2016 

ERN Neuromuscular Diseases 

199 902.94 

ERN Genetic Tumour Risk Syndromes 

100 260.50 

ERN Rare and Undiagnosed Skin Disorders 

200 000.00 

ERN Uncommon And Rare Diseases Of The Heart 

120 792.30 

ERN Rare Connective Tissue And Musculoskeletal 
Diseases Network 

199 749.95 

ERN Rare Adult Cancers 

ERN Rare Endocrine Conditions 

199 950.50 

200 000.00 

769036  —  VASCERN 
— ERN-SGA-2016 

ERN  Rare  Multisystemic  Vascular  Diseases 
(Vascern) 

199 977.86 

769039  —  ERN-LUNG 
— ERN-SGA-2016 

769040  —  ERN  BOND 
— ERN-SGA-2016 

769045  — 
ERN-
ITHACA — ERN-SGA-
2016 
769046  —  MetabERN 
— ERN-SGA-2016 

769048  —  ERN-RARE-
LIVER  —  ERN-SGA-
2016 
769051 — EpiCARE  — 
ERN-SGA-2016 

ERN Rare Respiratory Diseases 

ERN Bone Rare Diseases 

196 632.40 

200 000.00 

ERN  Rare  Congenital  Malformations  And  Rare 
Intellectual Disability 

185 916.00 

ERN Rare Hereditary Metabolic Diseases 

200 000.00 

ERN Rare Hepatological Diseases 

198 955.00 

ERN Rare And Complex Epilepsies 

195 975.18 

769056  —  ERN  RITA 
— ERN-SGA-2016 

ERN  Rare  Immunodeficiency,  Auto  inflammatory 
And Auto Immune Diseases 

200 000.00 

769057 — ERN-EYE — 
ERN-SGA-2016 

769064  — 
ERN-
EuroBloodNet  —  ERN-
SGA-2016 

ERN Rare Eye Diseases 

199 921.00 

ERN Rare Haematological Diseases 

199 853.32 

769070  —  CRANIO  — 
ERN-SGA-2016 

ERN  Rare  Craniofacial  Anomalies  and  Ent 
Disorders 

188 812.20 

769076  —  ERNICA  — 
ERN-SGA-2016 

ERN Inherited And Congenital Anomalies 

200 000.00 

42 

 
 
ERN 
770411  — 
TRANSPLANT  Child 
— ERN-SGA-2016 

Chafea  TOTAL  ERN 
SGAs 

ERN Transplantation In Children 

200 000.00 

4 386 344.15 

Operating grants 

Operating grants were awarded to non-profit organisations or networks that: 

 

 

are non-governmental; 

are non-profit-making and independent of industry, commercial and business or other conflicting 

interests; 

  work in the public health area; 

  play an effective role in civil dialogue processes at EU level; 

  pursue at least one of the health programme's specific objectives; 

 

are active at EU level and in at least half of the Member States; and 

  have a balanced geographical coverage of the EU. 

The  maximum  EU  contribution  is  60%  of  their  annual  operating  costs,  but  it  may  increase  to  80%  if  a 
proposal  meets  the  criteria  for  exceptional  utility.  In  2016,  only  six  operating  grants  qualified  for 
exceptional utility. 

At  the  start  of  the  third  health  programme,  Chafea  introduced  the  call  for  a  multiannual  ‘framework 

partnership’  whereby  the  holders  of  three-year  framework  partnership  agreements  (FPAs)  can  apply  for 

annual co-funding. 

The AWP 2016 did not plan for an open call for operating grants, as organisations that signed an FPA for 

2015-2017 were invited to submit their specific grant agreement (SGA) proposals covering their costs for 

2017. Of the 14 applicants granted an FPA, only 13 received an SGA. One of the FPA holders could not 

submit their SGA proposal for 2016 due to the bankruptcy of the legal entity hosting the specific network 

of experts. 

At  the  end  of  2016,  the  grant  preparation  process  was  completed,  corresponding  to  an  amount  of 

EUR 5 142 328. 

All the operating grants funded are listed by objective and by priority in the below table. 

43 

 
 
 
 
 
 
 
Financial instrument  Chafea operating grants by objective 
Objective: 
Description 
objective: 

1 
To  promote  health,  prevent  diseases  and  foster 
lifestyles 
supportive  environments  for  healthy 
taking  into  account  the  ‘health  in  all  policies’ 
principle. 

of 

Thematic priority: 

1.1  Cost-effective  promotion  and  prevention 
measures  in  line,  in  particular,  with  the  EU 
strategies on alcohol and nutrition 

User reference 

Title 

743838  —  OBTAINS-
E — SGA-01-2016 

746983  —  EPHA 
SGA-2017 — SGA-01-
2016 
747248  —  SFP  SGA 
2017 — SGA-01-2016 

748101 
— 
Vulnerability  NW  — 
SGA-01-2016 
748241  —  ENSP  FY 
2017 — SGA-01-2016 

— 
748817 
SOEEF2017  —  SGA-
01-2016 
Total 
Thematic priority: 

User reference 

747318  —  TBEC  — 
SGA-01-2016 
748531  —  AAE  — 
SGA-01-2016 
Total 
Thematic priority: 

User reference 

Amount 
committed  in 
EUR 
181 623.00 

Obesity Training and Information Services 

European Public Health Alliance 

662 661.00 

Smoking  prevention  in  action:  The  Smoke  Free 
Partnership Coalition 

485 095.00 

European  Network  to  Reduce  Vulnerabilities  In 
Health 

326 808.00 

European  Network  for  Smoking  and  Tobacco 
Prevention 

441 460.00 

Special Olympics Europe Eurasia Foundation 

170 176.00 

1.3  Support  effective  responses  to  communicable 
diseases  such  as  HIV/AIDS,  tuberculosis  and 
hepatitis 
Title 

Tuberculosis Europe Coalition 

AIDS Action Europe 

1.4  Support  cooperation  and  networking  in  the 
EU in relation to preventing and improving  the 
response to chronic diseases 
Title 

2 267 823.00 

Amount 
committed  in 
EUR 
79 702.00 

239 197.00 

318 899.00 

Amount 
committed  in 
EUR 
445 422.00 

323 015.00 

742885  —  AE2017  — 
SGA-01-2016 
747456  —  ECL  SGA  Cancer Leagues 

Alzheimer Europe 

44 

 
 
 
 
 
 
 
 
 
 
 
2017 — SGA-01-2016 
Total 
Objective: 
Description 
objective: 
Thematic priority: 

of 

User reference 

— 
748373 
SGA 
EURORDIS 
2017 — SGA-01-2016 
Total 
Thematic priority: 

User reference 

747144  —  EPF  2017 
WP — SGA-01-2016 
Total 
Thematic priority: 

User reference 

748399 
— 
HAI_FY2017 — SGA-
01-2016 
Total 
Chafea 
OPERATING 
GRANTS 

TOTAL 

4 
To  facilitate  access  to  better  and  safer  healthcare 
for EU citizens. 
4.2  Coordinated  action  at  EU  level  in  order  to 
effectively help patients affected by rare diseases 
Title 

Eurordis Rare Diseases Europe 

4.3  Strengthen  collaboration  on  patient  safety  and 
quality of health care 
Title 

European Patients’ Forum 

4.5  Implementation  of  EU  legislation  in  the  fields 
of  human  tissues  and  cells,  blood,  human  organs, 
medical  devices,  medicinal  products,  and  patients’ 
rights in cross-border health care 
Title 

Health Action International 

768 437.00 

Amount 
committed  in 
EUR 
792 323.00 

792 323.00 

Amount 
committed  in 
EUR 
741 846.00 

741 846.00 

Amount 
committed  in 
EUR 
253 000.00 

253 000.00 
5 142 328.00 

JOINT ACTIONS 
Grants  for  joint  actions  were  awarded  to  competent  authorities  or  public  sector  bodies  and  non-

governmental  bodies  mandated  by  those  competent  authorities.  The  maximum  EU  contribution  for  joint 

actions is 60%, but may go up to 80% if a proposal meets the criteria for exceptional utility. In 2016, four 

out of the five joint actions qualified for exceptional utility. 

The procedure for joint actions under the new health programme has changed. To assure more transparency 

and inclusiveness, the EU Member States and other countries participating in the third health programme 

45 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
nominate the competent authorities or other bodies. These nominated bodies are then invited to submit a 

proposal under the direct grant procedure. 

Five  joint  actions  were  co-funded  for  a  total  of  EUR 14 376 881.83.  Distribution  among  the  programme 

objectives was as follows: 

  Health promotion (4 joint actions): 

a.  JATC Tobacco control (EUR 1 999 018.07); 

b.  CHRODIS-PLUS Good practices for chronic diseases (EUR 4 999 999.56); 

c.  INTEGRATE  Integrating  prevention,  testing  and  linkage  to  care  strategies  across  HIV, 

viral hepatitis, TB and STIs in Europe (EUR 1 999 877.08), and 

d.  GAPP Facilitating the authorisation of preparation process for blood and tissues and cells 

(EUR 1 199 824.37). 

  Health threats (no joint actions) 

  Health systems (no joint actions) 

  Better  and  safer  healthcare  (1  joint  action):  JAMRAI  Antimicrobial  resistance  and  associated 

infections (EUR 4 178 162.75) 

Each  of  these  joint  actions  involved  between  27  and  44  beneficiaries  from  EU  and  other  countries 

participating in the programme. 

All the joint actions funded are listed by objective and by priority in the below table. 

Financial instrument  Chafea joint actions by objective 
Objective: 
Description 
objective: 

1 
To  promote  health,  prevent  diseases  and  foster  supportive 
environments  for  healthy  lifestyles  taking  into  account  the 
‘health in all policies’ principle. 

of 

Thematic priority: 

1.1 Cost-effective promotion and prevention measures in line, 
in particular, with the EU strategies on alcohol and nutrition 

User reference 

Title 

Amount 
committed  in 

46 

 
 
 
 
 
 
 
 
Tobacco Control 

Good practices for chronic diseases 

1.3 Support effective responses to communicable diseases such 
as HIV/AIDS, tuberculosis and hepatitis … 
Title 

Integrating  prevention,  testing  and  linkage  to  care  strategies 
across HIV, viral hepatitis, TB and STIs in Europe 

1.4 Support cooperation and networking in the EU in relation 
to preventing and improving the response to chronic diseases 
Title 

Facilitating  the  authorisation  of  preparation  process for  blood 
and tissues and cells 

4 
To  facilitate  access  to  better  and  safer  healthcare  for  EU 
citizens. 
4.4 Improve the prudent use of antimicrobial agents and reduce 
the practices that increase antimicrobial resistance 
Title 

Antimicrobial resistance and associated infections 

761297  —  JATC  — 
HP-JA-03-2016 

761307 — CHRODIS-
PLUS  —  HP-JA-02-
2016 
Total 
Thematic priority: 

User reference 

761319 
— 
INTEGRATE  —  HP-
JA-01-2016 
Total 
Thematic priority: 

User reference 

785269  —  GAPP  — 
HP-JA-05-2016 
Total 
Objective: 
Description 
objective: 
Thematic priority: 

of 

User reference 

EU-
761296  — 
JAMRAI  —  HP-JA-
04-2016 
Total 
Chafea 
JOINT ACTIONS 

TOTAL 

EUR 

1 999 018.07 

4 999 999.56 

6 999 017.63 

Amount 
committed  in 
EUR 
1 999 877.08 

1 999 877.08 

Amount 
committed  in 
EUR 
1 199 824.37 

1 199 824.37 

Amount 
committed  in 
EUR 
4 178 162.75 

4 178 162.75 
14 376 881.83 

DIRECT GRANT AGREEMENTS AND PRESIDENCY CONFERENCES 

47 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Direct grant agreements with international organisations were awarded to such organisations that are active 

in  the  area  of  public  health.  The  direct  grants  also  include  service-level  agreements.  The  maximum  EU 

contribution is 60%. 

Six direct grant agreements were signed by Chafea for a total amount of EUR 4 450 000 as follows: 

1)  Four  direct  grants  (EUR  2 150 000)  were  signed  with  the  WHO  for:  (i)  the  observatory  on 

dementia; (ii) the Framework Convention on Tobacco Control's (FCTC) Illicit Trade Protocol; (iii) 

migrants' health: best practices in care provision for vulnerable migrants and refugees; and (iv) the 

European  Observatory  on  Health  Systems  and  Policies  on  country  specific  knowledge  and 

antimicrobial resistance. 

2)  One direct grant (EUR 1 200 000) was signed with the OECD for the preparation of the EU health 

report ‘State of health in the EU’ and the country specific analysis. 

3)  One  direct  grant  (EUR  1 100 000)  was  signed  with  the  Council  of  Europe  on  European 

Pharmacopoeia (EDQM) (CoE — EDQM). 

All direct grant agreements funded are listed by objective and by priority in the below table. 

Financial instrument  Chafea direct grant agreements by objective 
Objective: 
Description 
objective: 

1 
To  promote  health,  prevent  diseases  and  foster  supportive 
environments  for  healthy  lifestyles  taking  into  account  the 
‘health in all policies’ principle. 

of 

Thematic priority: 

1.4 Support cooperation and networking in the EU in relation 
to preventing and improving the response to chronic diseases 

User reference 

Title 

20165101 — WHO 

EU contribution to the WHO Observatory on dementia 

Total 
Thematic priority: 

User reference 

1.5 Actions required by, or contributing to, the implementation 
of EU legislation in the field of tobacco products 
Title 

Amount 
committed 
EUR 
500 000.00 

in 

500 000.00 

Amount 
committed 

in 

48 

 
 
 
 
 
 
 
 
 
 
20165102 — WHO 

FCTC  The  Framework  Convention  on  Tobacco  Control 
(FCTC) Illicit Trade Protocol  

Total 
Objective: 
Description 
objective: 
Thematic priority: 

User reference 

20165401 — WHO 

Total 
Thematic priority: 

User reference 

20165302  —  Council 
of Europe 
Total 
Thematic priority: 

of 

3 
To  contribute  to  innovative,  efficient  and  sustainable  health 
systems. 
3.4.  Provide  expertise  and  share  good  practices  to  assist 
Member States undertaking health system reforms … 
Title 

WHO  host  of  the  European  Observatory  on  Health  Systems 
and Policies on country specific knowledge and antimicrobial 
resistance 

3.6  Implementation  of  EU  legislation  in  the  field  of  medical 
devices, medicinal products and cross-border health care 
Title 

European Pharmacopoeia (EDQM) 

3.7.  Foster  a  health  information  and  knowledge  system  to 
contribute to evidence-based decision making 

User reference 

Title 

Migrants health: Best practices in care provision for vulnerable 
migrants and refugees  
Preparation  of  EU  health  report  —  ‘State  of  health  in  the 
European Union’ and country specific analysis 

20165103 — WHO 

20165303 — OECD 

Total 
Chafea 
DIRECT GRANTS 

TOTAL 

Presidency conferences 

EUR 
400 000.00 

400 000.00 

Amount 
committed 
EUR 
750 000.00 

in 

750 000.00 

Amount 
committed 
EUR 
1 100 000.00 

in 

1 100 000.00 

Amount 
committed 
EUR 
500 000.00 

in 

1 200 000.00 

1 700 000.00 
4 450 000.00 

The  Presidency  conferences  financed  under  AWP  2016  included  a  conference  under  the  Slovakian 

Presidency  on  ‘Structured  Cooperation  between  Health  Care  Systems’  for  100 000  EUR  and  a  technical 

meeting on ‘Childhood Obesity’ under the Maltese Presidency for 41 780.43 EUR. See below table. 

Financial instrument  Chafea Presidency conferences by objective 

49 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Objective: 
Description 
objective: 

of 

1 
To  promote  health,  prevent  diseases  and  foster  supportive 
environments  for  healthy  lifestyles  taking  into  account  the 
‘health in all policies’ principle. 

Thematic priority: 

1.1 Cost-effective promotion and prevention measures in line, 
in particular, with the EU strategies on alcohol and nutrition 

User reference 

Title 

739556  —  Malta  2017 
— PC2-01-2016 

Structured  Cooperation  between  Health  Care  Systems  and 
Childhood Obesity 

Total 
Thematic priority: 

User reference 

740104  —  SK  PRES 
— PC1-01-2016 
Total 
Chafea 
PRESIDENCY 
CONFERENCES 

TOTAL 

1.4 Support cooperation and networking in the EU in relation 
to preventing and improving the response to chronic diseases 
Title 

Prevention of chronic non-communicable diseases and healthy 
lifestyles and Alzheimer’s disease 

Amount 
committed  in 
EUR 
100 000.00 

100 000.00 

Amount 
committed  in 
EUR 
41 780.43 

41 780.43 
141 780.43 

PROCUREMENTS (SERVICE CONTRACTS) 
Procurement (service contracts) was used to purchase services for a total amount of EUR 16 089 842.38. 

Contrary to the grants, the health programme covers the full cost of the procurement. 

These service contracts cover needs as specified in the AWP 2016, namely: 

 

 

evaluation and monitoring of actions and policies; 

studies; 

  provision of advice; 

  data and information on health; 

 

 

 

 

scientific and technical assistance; 

communication; 

awareness raising and dissemination of the results; and 

information technology applications in support of policies. 

50 

 
 
 
 
 
 
 
 
 
 
 
 
In  2016,  DG  SANTE  signed  several  service  contracts  and  specific  requests  using  existing  framework 

contracts. Most of these contracts and requests were for horizontal actions such as communication and IT 

services for maintenance and functioning of existing IT tools. 

Procurement  contracts  also  included  contracts  with  experts  working  for  the  scientific  committees  and 

evaluation  and  monitoring  studies.  The  overall  public  procurement  budget  implemented  by  DG  SANTE 

under AWP 2016 was EUR 5 633 778.84. 

The overall public procurement budget implemented by Chafea under AWP 2016 was EUR 10 456 063.54. 
In 2016, Chafea managed 26 new market procedures for the acquisition of services (five contracts under 
health promotion, four contracts under health threats, five contracts under health systems and three under 
better and safer health care) and nine on horizontal communication. 

The amounts per objective and authorising organisation were as follows: 

Health 

programme 

Procurement 

Procurement 

objective 

managed 

by  DG 

managed  by  Chafea 

SANTE 

 (EUR) 

(EUR) 

Health promotion 

1 211 291.31 

1 748 994.60 

Health threats 

0.00 

3 912 709.30 

Health systems 

1 478 981.80 

2 148 175.00 

Better 

and 

safer 

364 999.69 

1 646 638.27 

healthcare 

Horizontal 

TOTAL 

2 578 506.04 

999 546.37 

5 633 778.84 

10 456 063.54 

The  table  below  lists  all  service  contracts  signed  per  objective  and  per  priority  by  Chafea  and  by  DG 

SANTE. 

Financial instrument 
Objective: 
Description of objective: 

Thematic priority: 

Chafea calls for tender by objective 
1 
To promote health, prevent diseases and foster supportive 
environments for healthy lifestyles taking into account the 
‘health in all policies’ principle. 

1.1  Cost-effective  promotion  and  prevention  measures  in 
line,  in  particular,  with  the  EU  strategies  on  alcohol  and 
nutrition 

51 

 
 
 
 
 
 
 
User reference 

Title 

RfS 

20167101  — 
Chafea/2016/Health/01 
(under 
FWC 
EAHC/2013/HEALTH/01 
lot 1) 

Total 
Thematic priority: 

User reference 

20167120  —  Open  call 
Chafea/2016/Health/03  
Total 
Thematic priority: 

User reference 

20167120  —  Open  call 
Chafea/2016/Health/03  
Total 
Thematic priority: 

User reference 

RfS 

20157105  — 
Chafea/2015/Health/40 
FWC 
the 
(under 
DI/07171 ABCIII LOT2)  
FWC82 
Chafea/2016/Health/36 
— Framework contract  
Total 
Objective: 
Description of objective: 

Thematic priority: 

User reference 

Childhood obesity 

1.3 Support effective responses to communicable diseases 
such as HIV/AIDS, tuberculosis and hepatitis 
Title 

Trainers Migrants Health 

1.4  Support  cooperation  and  networking  in  the  EU  in 
relation  to  preventing  and  improving  the  response  to 
chronic diseases 
Title 

Trainers Migrants Health 

required  by,  or  contributing 

the 
1.5  Actions 
implementation  of  EU  legislation  in  the  field  of  tobacco 
products 
Title 

to, 

EU system for traceability and security features in the field 
of tobacco products. 

Amount 
committed  in 
EUR 
199 924.00 

199 924.00 

Amount 
committed  in 
EUR 
499 940.00 

499 940.00 

Amount 
committed  in 
EUR 
499 940.00 

499 940.00 

Amount 
committed  in 
EUR 
549 190.60 

Support  the  assessment  of  characterising  flavours  in 
tobacco products 

0.00 

2 
To  protect  EU  citizens  from  serious  cross-border  health 
threats. 
2.2  Support  capacity  building  against  health  threats  in 
Member States 
Title 

549 190.60 

Amount 
committed  in 

82 
been committed under this FWC in 2016. 

The framework contract (FWC) of a value of EUR 2 071 900 was signed. No specific contract has 

52 

 
 
 
 
 
 
 
 
 
 
 
 
                                                      
RfS 

RfS 

FWC 

20167201  — 
Chafea/2016/Health/13 
(under 
Chafea/2015/Health/05-
Lot1)  
20167202  — 
Chafea/2016/Health/14 
(under 
Chafea/2015/Health/05-
Lot 2)  
20167203  — 
Chafea/2016/Health/15 
(under 
Chafea/2015/Health/05-
Lot2)  
20167204  —  Open  call 
Chafea/2016/Health/12 
Total 
Objective: 
Description of objective: 

FWC 

RfS 

Thematic priority: 

User reference 

RfS 

FWC 

20167102  — 
Chafea/2016/Health/16 
(under 
EAHC/2013/Health/01-
Lot 1)  
Total 
Thematic priority: 

User reference 

RfS 

FWC 

20167205  — 
Chafea/2016/Health/17 
(under 
EAHC/2013/Health/01-
Lot 1)  
Total 
Thematic priority: 

User reference 

Table top exercise 

EUR 
292 954.03 

Workshop state of play of EU health preparedness 

245 000.00 

Workshop on vector borne diseases 

244 271.27 

Training  for  health  professionals  with  migrants  and 
refugees 

3 130 484.00 

3 912 709.30 

3 
To  contribute  to  innovative,  efficient  and  sustainable 
health systems. 
3.1 Support voluntary cooperation between Member States 
on health technology assessment 
Title 

Health reports: Health Technology assessment (HTA) 

3.2 Promote the voluntary uptake of health innovation and 
eHealth  by  increasing  the  interoperability  of  patient 
registries and other eHealth solutions 
Title 

Market study on telemedicine eHealth 

3.3  Support  the  sustainability  of  the  health  workforce  by 
developing  effective  health  workforce  forecasting  and 
planning  
Title 

Amount 
committed  in 
EUR 
383 400.00 

383 400.00 

Amount 
committed  in 
EUR 
283 950.00 

283 950.00 

Amount 
committed  in 
EUR 

53 

 
 
 
 
 
 
 
 
 
 
20167301  —  Open  call 
Chafea/2016/Health/18 
Total 
Thematic priority: 

User reference 

RfS 

FWC 

RfS 

FWC 

20167103  — 
Chafea/2016/Health/22 
(under 
EAHC/2013/Health/01-
Lot 2)  
20167401  — 
Chafea/2016/Health/27 
(under 
EAHC/2013/Health/01-
Lot 2)  
Total 
Objective: 
Description of objective: 

Thematic priority: 

User reference 

RfS 

RfS 

FWC 

20167105  — 
Chafea/2016/Health/31 
(under 
Chafea/2015/Health/09)  
20167106  — 
Chafea/2016/Health/32 
(under 
Chafea/2015/Health/09) 
20167107  — 
Chafea/2016/Health/33 
(under 
Chafea/2015/Health/09)  
Total 
Objective: 
Description of objective: 

FWC 

FWC 

RfS 

Thematic priority: 
User reference 

Support health workforce planning 

3.6  Implementation  of  EU  legislation  in  the  field  of 
medical  devices,  medicinal  products  and  cross-border 
health care 
Title 

Health economics: cross-border cooperation 

976 730.00 

976 730.00 

Amount 
committed  in 
EUR 
254 570.00 

Health economics: information to patients  

249 525.00 

4 
To  facilitate  access  to  better  and  safer  healthcare  for  EU 
citizens. 
4.1  Support  the  establishment  of  a  system  of  European 
Reference Networks for patients with conditions requiring 
highly specialised care 
Title 

Assessment  of  European  Reference  Network  (ERN) 
applications 

504 095.00 

Amount 
committed  in 
EUR 
1 066 458.59 

Assessment  of  European  Reference  Network  (ERN) 
applications 

462 701.68 

Assessment  of  European  Reference  Network  (ERN) 
applications 

117 478.00 

5 
IT  /  dissemination  (horizontal  action  related  to  all 
objectives)  
horizontal IT / dissemination 
Title 

1 646 638.27 

Amount 
committed  in 
EUR 
1 800.00 

20167108  —  Low  value 
contract 

Dissemination  activity:  the  Public  Health  England  annual 
conference 

54 

 
 
 
 
 
 
 
 
 
 
 
 
RfS 

FWC 

20167109  —  Low  value 
contract 
20167111  —  Low  value 
contract  
20167114  —  Specific 
Contract 
Chafea/2016/Health/61 
(under FWC DI/07330 — 
Lot 1) 
20167115  — 
Chafea/2016/Health/53 
(under 
Chafea/2013/Health/14) 
20167116  — 
Chafea/2016/Health/54 
(under 
Chafea/2013/Health/14)  
20167117  — 
Chafea/2016/Health/55 
(under 
FWC 
SANCO/2012/04/009  Lot 
1)  
20167126  —  Low  value 
contract  
20167127  —  Low  value 
contract  
Total 
Chafea  TOTAL  CALLS 
FOR TENDER 

FWC 

RfS 

RfS 

Dissemination activity: Gastein 2016 

24 972.50 

Dissemination 
Conference 
Database 
Agency 

activity:  European 

Public  Health 

17 750.00 

Developer 

for 

the 

Executive 

99 510.40 

Dissemination  activity:  EUPHA  conference  November 
2016, Vienna 

59 998.95 

Dissemination activity: 10 events 

434 955.42 

Dissemination activity: brochures and info sheets 

338 564.10 

Dissemination activity: workshop on health and ageing 

11 600.00 

Dissemination  activity:  congress  of  clinical  microbiology 
and infectious diseases 

10 395.00 

999 546.37 
10 456 063.54 

Financial Instrument 
Objectives: 
Description of objective:  To  promote  health,  prevent  diseases  and  foster  supportive 
environments  for  healthy  lifestyles  taking  into  account  the 
‘health in all policies’ principle. 

SANTE calls for tender by objective 
1 

Thematic priority: 

User reference 

1.1  Cost-effective  promotion  and  prevention  measures  in 
line,  in  particular,  with  the  EU  strategies  on  alcohol  and 
nutrition 
Title 

C4  —  SI2.772013  —  SANTE/2017/C4/022  — 
MONITORING AND RELATED SERVICES OF THE EU 
PLATFORM  FOR  ACTION  ON  DIET  PHYSICAL 
ACTIVITY  AND  HEALTH  2016-2019  AND  EU 
ALCOHOL&HEALTH FORUM 2017-2019 
C4  —  WEB  ACTIVITIES  FOR  THE  HEALTH  POLICY 
FORUM 
SC 8264 — RG — DATABASE DEVELOPER (CD) 

Total 

55 

Amount 
committed  in 
EUR 
346 149.00 

150 000.00 

49 895.71 
546 044.71 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thematic priority: 

User reference 

required  by,  or  contributing 

the 
1.5  Actions 
implementation  of  EU  legislation  in  the  field  of  tobacco 
products 
Title 

to, 

B2  -  17.030100  —  CONFORMITY  ASSESSMENT  OF 
THE TRANSPOSITION OF THE TOBACCO PRODUCTS 
DIRECTIVE — TIPIK — DEG 
B2 
17.030100  —  EUROBAROMETER  ON 
MONITORING OF TOBACCO PRODUCTS DIRECTIVE 
— TNS/KANTAR 

- 

Total 
Objective: 
Description of objective:  To contribute to innovative, efficient and sustainable health 

3 

Thematic priority: 

User reference 

systems. 
3.6 Implementation of EU legislation in the field of medical 
devices, medicinal products and cross-border health care 
Title 

FOR 

FOR 

FOR 

POINTS 

POINTS 

MEASURES 
LEGISLATION 

B3  -  17.030100  —  CONFERENCE  OF  NATIONAL 
CONTACT 
CROSS-BORDER 
HEALTHCARE 
B3  -  17.030100  —  CONFERENCE  OF  NATIONAL 
CONTACT 
CROSS-BORDER 
HEALTHCARE — TRANSPORTATION AND HOTEL — 
AMEX — DEG 
B3  -  17.030100  —  CONFERENCE  OF  NATIONAL 
CONTACT 
CROSS-BORDER 
POINTS 
HEALTHCARE -CATERING — SODEXO 
B4  -  17.030100  —  SANTE/2016/B4/052  —  STUDY  ON 
RE 
TRANSPOSITION 
PHARMACEUTICAL 
— 
TECHNOPOLIS 
FOR  CROSS-BORDER  HEALTHCARE 
DINNER 
EXPERT  GROUP  ON  23/10/2016  —  THON  HOTEL  — 
COMPL 
GROW.R.3  —  CS  9309  —  CC  DI/7335  —  INNOVATIA 
— GEORGIEVA — E-ORDER 7099 — EUDAMED 
GROW/R3  —  CS  5126  —  CC  DI/7330  —  SHAH  — 
EURORA-1  
GROW/R3 — CS 5887 — CC DI/7331 — PANOPLYS — 
FLORESCU — TIMPERIO 
GROW/R3  —  CS  5961  —  CC  DI7330  —  EURORA-1  — 
PALUMBO  
GROW/R3 — CS 5963 — CC DI/7335 — INNOVATIA — 
TUZUNOGLU  
GROW/R3 — CS 5964 — CC DI/7330 — EURORA-1 — 
VAN BELLINGHEN  
GROW/R3 — CS 5966 — CC DI/7331 — PANOPLYS — 
AUCLERT 

56 

Amount 
committed  in 
EUR 
314 791.72 

350 454.88 

665 246.60 

Amount 
committed  in 
EUR 
788.72 

48 844.10 

4 342.00 

129 300.00 

1 289.40 

56 875.20 

41 868.00 

7 870.50 

23 313.42 

74 613.40 

12 936.04 

18 469.76 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GROW/R3  —  CS  6263  —  CC  DI/7331  —  PANOPLYS 
— HOULIHAN  
GROW/R3 — CS 6316 — CC DI/7338 — ONE4EU3 — 
GUEBEL  
GROW/R3 — CS 6400 -CC DI/7335 — INNOVATIA — 
SAITAS  
GROW/R3  —  CS  6839  —  CC  DI/7331  —  PANOPLYS 
— HENNECART  
GROW/R3 — CS 695 — CC DI/7390 — SINCRONIT — 
BENLARBI  
GROW/R3 — CS 7064 — CC DI/7330 — EURORA-1 — 
SHAH 
GROW/R3 — CS 7364 — CC DI/7335 — INNOVATIA 
— FERNANDEZ Y GARCIA 
GROW/R3 — CS 8070 — CC DI/7335 — INNOVATIA 
— FOTIADIS  
GROW/R3  —  CS  8373  —  CC  DI/7333  —  RATOI  — 
EUROPEAN DYNAMICS 
GROW/R3 — CS 8429 — CC DI/7330 — EURORA-1 — 
VAN BELLINGHEN  
GROW/R3 — CS 8435 — CC DI/7330 — EURORA-1 — 
SHAH 
GROW/R3  —  CS  8760  —  CC  DI/7331  —  MORO  — 
PANOPLYS 
SC  4468  —  PH  —  PROJECT  MANAGER  FOR  IT 
HEALTH — AV1 
SC  6389  —  DB —  APPLICATION  ARCHITECT FOR 
WINDOWS CONSULTANCY SERVICES — MOD BA 
SC  702  —  RD  —  TEAM  COORDINATOR  FOR  EMP 
PROJECTS 

3.7.  Foster  a  health  information  and  knowledge  system  to 
contribute to evidence-based decision making 
Title 

C2  -  17.030100  —  SUPPORT  OF  2  WEB/VISUAL 
DESIGNERS  TO  PROVIDE  ASSISTANCE  TO 
SCIENTIFIC COMMITTEES — NOVACOMM 
C2  -  17030100  —  SCIENTIFIC  AND  TECHNICAL 
ASSISTANCE  FOR  SCIENTIFIC  COMMITTEES  — 
DEG 

Total 
Thematic priority: 

User reference 

Total 
Objective: 
Description of objective:  To  facilitate  access  to  better  and  safer  healthcare  for  EU 

4 

Thematic priority: 

citizens 
4.1  Support  the  establishment  of  a  system  of  European 
Reference  Networks  for  patients  with  conditions  requiring 
highly specialised care 

126 447.20 

19 452.76 

132 528.00 

3 174.40 

6 872.80 

25 120.80 

57 432.80 

111 520.00 

24 919.40 

7 463.10 

83 736.00 

64 644.00 

5 000.00 

99 843.60 

130 156.40 

1 318 821.80 

Amount 
committed  in 
EUR 
146 000.00 

14 160.00 

160 160.00 

User reference 

Title 

Amount 

57 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B3  -  17.030100  —  ORGANISATION  OF  THE  3RD  ERN 
CONFERENCE IN VILNIUS — MARCH 2017 — TIPIK 
SC 6384 — CF — PROJECT MANAGER FOR HEALTH 
PROJECTS + AV1 — MOD BA 

committed  in 
EUR 
339 999.69 

25 000.00 

364 999.69 
5 633 778.84 

Total 
SANTE 
TOTAL 
CALLS FOR TENDER 

OTHER ACTIONS 
EUR 3 313 500  was  earmarked  for  other  actions in 2016. The  ‘other  actions’  include  experts’ fees.  For 

example, fees: 

 

 

 

for experts in the expert panel on effective ways of investing in health; 

for experts carrying out system inspection on pharmaceutical ingredients; 

for  experts  participating  in  the  international  conferences  on  the  harmonisation  of  technical 

requirements for the registration of pharmaceuticals for human and veterinary uses. 

This  category  also  includes  the  cost  of  administrative  agreements  with  the  Joint  Research  Centre  and 

covers the Commission’s membership fee to the European Observatory on Health Systems and Policies. 

See the below table for more information on what specific actions fell under ‘other actions’.  

Financial instrument 
Objective: 
Description of objective:  To contribute to innovative, efficient and sustainable health 

Chafea other actions by objective 
3 

Thematic priority: 

systems. 
3.7.  Foster  a  health  information  and  knowledge  system  to 
contribute to evidence-based decision making 

User reference 

Title 

20165301 
Observatory 

-European 

Commission  membership  fee  to  the  European  Observatory 
on Health Systems and Policies 

Chafea 
OTHER ACTIONS 

TOTAL 

Amount 
committed  in 
EUR 
500 000.00 

500 000.00 

Financial instrument 
Objective: 
Description 
objective: 

of 

SANTE other actions by objective 

1 
To  promote  health,  prevent  diseases  and  foster  supportive 
environments  for  healthy  lifestyles  taking  into  account  the 
‘health in all policies’ principle. 

58 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thematic priority: 

1.6  Foster  a  health  information  and  knowledge  system  to 
contribute to evidence-based decision making 

User reference 

Title 

C1  -  17.030100  AA  WITH  JRC  No 34447  —  HARCAS  II: 
ACTIVITIES  IN  CANCER  RELATING  TO  CANCER 
REGISTRIES AND BREAST-CANCER SCREENING AND 
DIAGNOSIS GUIDELINES 

of 

2 
To  protect  EU  citizens  from  serious  cross-border  health 
threats. 
2.1 Improve risk assessment and close gaps in risk assessment 
capacities 

Total 
Objective: 
Description 
objective: 
Thematic priority: 

User reference 

Title 

SPECIAL 

SCIENTIFIC 
C3  — 
COMMITTEES  TO  PERFORM  RISK  ASSESSMENT  IN 
CASE OF CROSS-BORDER HEALTH THREAT 

INDEMNITIES 

Total 
Objective: 
Description 
objective: 
Thematic priority: 

User reference 

of 

3 
To  contribute  to  innovative,  efficient  and  sustainable  health 
systems. 
3.4.  Provide  expertise  and  share  good  practices  to  assist 
Member States undertaking health system reforms  
Title 

B1 - 17030100 — SPECIAL INDEMNITIES FOR EXPERT 
PANEL MEETINGS (MARCH 2016 — MAY 2017) — DEG 
C2 
-  17030100  —  SCIENTIFIC  COMMITTEES  — 
INDEMNITIES PAID TO EXPERTS — COMPL 

3.6  Implementation  of  EU  legislation  in  the  field  of  medical 
devices, medicinal products and cross-border health care 
Title 

Total 
Thematic priority: 

User reference 

Amount 
committed  in 
EUR 
1 800 000.00 

1 800 000.00 

Amount 
committed  in 
EUR 
35 000.00 

35 000.00 

Amount 
committed  in 
EUR 
120 000.00 

170 000.00 

290 000.00 

Amount 
committed  in 
EUR 
200 000.00 

B5  —  SI2.728675  —  ICH  EXPERTS  2016  —  PARTIAL 
DECOMMITMENT 
B5  —  SI2.733920  —  GOOD  MANUFACTURING 
PRACTICES  (GMP)  INSPECTIONS  —  JOINT  AUDIT 
PROGRAMME (JAP) 
B5  —  SI2.742175  -  2016  AND  2017  MEMBERSHIP  FEE 
TO THE ICH — DEG —  
DEG=E5 
ATTENDANCE VICH MEETINGS IN 2016 
F5 — REIMBURSEMENT OF EXPERTS’ EXPENSES FOR  75 000.00 

17030100  — 

(EX-B5)  — 

EXPERTS 

35 000.00 

8 500.00 

350 000.00 

59 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
JOINT ASSESSMENT — MEDICAL DEVICES — COMPL 
F5 — SI2.728732 — API: SYSTMES AUDITS — DEG - 

20 000.00 
688 500.00 
2 813 500.00 

Total 
SANTE 
OTHER ACTIONS 

TOTAL 

60 

 
 
 
 
 
 
 
 
DETAILED OVERVIEW OF THE REPORTING YEAR 

Funding per thematic priority and financial instrument (all amounts in EUR) 

Objective 1: 

Description of objective: To promote health, prevent diseases and foster supportive environments for healthy lifestyles taking into account the 
‘health in all policies’ principle. 

health 

Third 
programme 
Thematic 
priorities 

Chafea 
project 
grants 
objective 

by 

Chafea 
ERN 
SGAs 
under 
FPA  by 
objective 

Chafea 
operating 
grants 
objective 

by 

Chafea  joint 
by 
actions 
objective 

Chafea 
direct grant 
agreements 
by 
objective 

Chafea 
Presidency 
conferences 
by objective 

Chafea 
other 
actions 
by 
objective  

SANTE 
other actions 
by objective  

Chafea 
for 
calls 
tender  by 
objective  

SANTE 
calls 
tender 
objective  

for 
by 

Total 

and 

Cost-

1.1 
effective 
promotion 
prevention 
measures  in  line, 
in particular, with 
the  EU  strategies 
on  alcohol  and 
nutrition 
1.2  Measures  to 
complement 
the 
Member  States’ 
in 
action 
drug-
reducing 
related 
health 
damage 

3 782 312.44 

0.00 

2 267 823.00 

6 999 017.63 

0.00 

100 000.00 

0.00 

0.00 

199 924.00 

546 044.71 

13 895 121.78 

599 511.79 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

599 511.79 

61 

 
 
 
 
 
 
 
 
 
 
to 

Support 

1.3 
effective 
responses 
communicable 
diseases  such  as 
HIV/AIDS, 
tuberculosis  and 
hepatitis 
1.4 
Support 
cooperation  and 
networking in the 
EU  in  relation  to 
and 
preventing 
the 
improving 
response 
to 
chronic diseases 

1.5 
Actions 
required  by,  or 
contributing 
to, 
the 
implementation 
of  EU  legislation 
in 
the  field  of 
tobacco products 
a 
1.6 
health 
information  and 
knowledge 
system 
contribute 
evidence-based 
decision making, 
Total 

Foster 

to 
to 

0.00 

0.00 

318 899.00 

1 999 877.08 

0.00 

0.00 

0.00 

0.00 

499 940.00 

0.00 

2 818 716.08 

1 884 548.42 

0.00 

768 437.00 

1 199 824.37 

500 000.00 

41 780.43 

0.00 

0.00 

499 940.00 

0.00 

4 894 530.22 

0.00 

0.00 

0.00 

0.00 

400 000.00 

0.00 

0.00 

0.00 

549 190.60 

665 246.60 

1 614 437.20 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

1 800 000.00 

0.00 

0.00 

1 800 000.00 

6 266 372.65 

0.00 

3 355 159 

10 198 719.08 

900 000 

141 780.43 

0.00 

1 800 000 

1 748 994.6 

1 211 291.31 

25 622 317.07 

62 

 
 
 
 
 
Objective: 

Description 
objective: 

2 

of 

To protect EU citizens from serious cross-border health threats. 

health 

Third 
programme 
Thematic 
priorities 

Chafea 
project 
grants 
objective 

by 

Chafe
a ERN  
SGAs 
under 
FPA 
by 
objecti
ve 
0.00 

Chafea 
operating 
grants  by 
objective 

Chafea  joint 
actions 
by 
objective 

Chafea 
direct 
grant 
agreements 
by 
objective 

Chafea 
Presidency 
conference
s 
objective 

by 

Chafea 
other 
actions  by 
objective  

SANTE 
other 
actions by 
objective  

Chafea 
calls 
for 
tender  by 
objective  

SANTE 
calls 
for  tender  by 
objective  

Total 

0.00 

0.00 

0.00 

0.00 

0.00 

35 000.00 

0.00 

0.00 

35 000.00 

0.00 

2.1  Improve  risk 
and 
assessment 
close  gaps  in  risk 
assessment 
capacities 

2.2 
Support 
capacity  building 
against 
health 
threats  in  Member 
States 
Total 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

3 912 709.3
0 

0.00 

3 912 709.30 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

35 000.00 

3 912 709.3
0 

0.00 

3 947 709.30 

63 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Objective: 

Description 
objective: 

3 

of 

To contribute to innovative, efficient and sustainable health systems. 

health 

Third 
programme 
Thematic 
priorities 

Chafea 
project 
grants 
objective 

by 

0.00 

Chafea 
ERN 
SGAs 
under 
FPA 
objective 
0.00 

by 

Chafea 
operating 
grants  by 
objective 

Chafea  joint 
actions 
by 
objective 

Chafea 
direct  grant 
agreements 
by objective 

Chafea 
Presidency 
conferences 
by 
objective 

Chafea 
other 
actions  by 
objective  

SANTE 
other 
actions  by 
objective  

Chafea calls 
for 
tender 
by objective  

SANTE 
calls 
tender 
objective  

for 
by 

Total 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

383 400.00 

0.00 

383 400.00 

Support 

3.1 
voluntary 
cooperation 
between  Member 
States  on  health 
technology 
assessment 
3.2  Promote  the 
voluntary  uptake 
health 
of 
and 
innovation 
by 
eHealth 
increasing 
the 
interoperability  of 
patient 
registries 
and  other  eHealth 
solutions 
3.3  Support 
the 
sustainability  of 
health 
the 
by 
workforce 
developing 
effective 
workforce 
forecasting 
planning  

health 

and 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

283 950.00 

0.00 

283 950.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

976 730.00 

0.00 

976 730.00 

64 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
system 

Provide 
3.4. 
and 
expertise 
share 
good 
practices  to  assist 
Member 
States 
undertaking 
health 
reforms 
3.6 
Implementation 
of  EU  legislation 
in 
the  field  of 
medical  devices, 
medicinal 
products 
cross-border 
health care 
3.7. 
health 
information 
knowledge 
system 
contribute 
evidence-based 
decision making 
Total 

Foster 

to 
to 

and 

and 

a 

0.00 

0.00 

0.00 

0.00 

750 000.00 

0.00 

0.00 

290 000.00  0.00 

0.00 

1 040 000.00 

0.00 

0.00 

0.00 

0.00 

1 100 000.00  0.00 

0.00 

688 500.00  504 095.00 

1 318 821.80  3 611 416.80 

0.00 

0.00 

0.00 

0.00 

1 700 000.00  0.00 

500 000.00 

0.00 

0.00 

160 160.00 

2 360 160.00 

0.00 

0.00 

0.00 

0.00 

3 550 000.00  0.00 

500 000.00 

978 500.00  2 148 175.00  1 478 981.80  8 655 656.80 

Objective: 

Description 
objective: 

4 

of 

To facilitate access to better and safer healthcare for EU citizens. 

health 

Third 
programme 
Thematic 
priorities 

Chafea 
project 
grants 
objective 

by 

Chafea 
ERN  SGAs 
under  FPA 
by objective 

Chafea 
operating 
grants 
objective 

by 

Chafea 
joint actions 
by objective 

Chafea 
direct 
grant 
agreements 
by 

Chafea 
Presidency 
conferences 
by 
objective 

Chafea 
other 
actions  by 
objective  

SANTE 
other 
actions by 
objective  

Chafea calls 
for 
tender 
by objective  

SANTE 
calls 
for 
tender  by 
objective  

Total 

65 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
highly 

for 
with 

4.1  Support 
the 
establishment  of  a 
system 
of 
European 
Reference 
Networks 
patients 
conditions 
requiring 
specialised care 
4.2  Coordinated 
action  at  EU  level 
to 
in 
order 
help 
effectively 
patients 
affected 
by rare diseases 
Strengthen 
4.3 
collaboration 
on 
patient  safety  and 
quality  of  health 
care 
Improve 
4.4 
prudent 
use 
antimicrobial 
agents  and  reduce 
the  practices  that 
increase 
antimicrobial 
resistance 

the 
of 

objective 

0.00 

4 386 344.15  0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

1 646 638.27  364 999.69  6 397 982.11 

2 528 839.39 

0.00 

792 323.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

3 321 162.39 

0.00 

0.00 

741 846.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

741 846.00 

0.00 

0.00 

0.00 

4 178 162.75  0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

4 178 162.75 

66 

 
 
4.5 
Implementation  of 
EU  legislation  in 
the fields of human 
tissues  and  cells, 
blood, 
human 
organs,  medical 
devices,  medicinal 
products, 
and 
patients’  rights  in 
cross-border health 
care 
Total 

0.00 

0.00 

253 000.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

253 000.00 

2 528 839.39 

4 386 344.15  1 787 169.00  4 178 162.75  0.00 

0.00 

0.00 

0.00 

1 646 638.27  364 999.69  14 892 153.25 

Objective: 

5 

Description 
objective: 
Third 
Programme 
Thematic 
priorities 

health 

of 

IT / dissemination (horizontal action related to all objectives)  

Chafea 
project 
grants 
objective 

by 

Chafea ERN 
SGAs  under 
by 
FPA 
objective 

Chafea 
operating 
grants 
objective 

by 

Chafea 
joint 
actions  by 
objective 

Horizontal 
dissemination 

IT 

/ 

0.00 

Total 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

Chafea 
Presidency 
conferences 
by 
objective 

Chafea 
other 
actions  by 
objective  

SANTE 
other 
actions 
objective  

by 

Chafea 
calls 
for 
tender  by 
objective  

SANTE 
calls 
tender 
objective  

for 
by 

Total 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

999 546.37  2 578 506.04  3 578 052.41 

999 546.37  2 578 506.04  3 578 052.41 

Chafea 
direct 
grant 
agreements 
by 
objective 
0.00 

0.00 

67 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL AMOUNT COMMITTED BY CHAFEA UNDER AWP 2016 

48 248 609.99 

TOTAL AMOUNT COMMITTED BY DG SANTE UNDER AWP 2016 

8 447 278.84 

TOTAL COMMITTED  

56 695 888.83 

68